UNIVERSITY OF MICHIGAN W.K. KELLOGG EYE CENTER 2 012 ANNUAL REPORT
Preventi n g CURING
Highlights annual report 2012
LEADERSHIP 4 Dr. Paul Lee talks about new
ways of working in a changing health care environment
PATIENT CARE 7 A patient with Graves’ eye
disease has Kellogg’s multidisciplinary team on her side
8 A mother and daughter with
a rare inherited eye disease come to Kellogg for treatment
front cover: H. Kaz Soong, M.D., Donna Donato, Jonathan Trobe, M.D., Charlotte Bush, Brenda Bohnsack, M.D., Ph.D. back cover: Kristen Harris Nwanyanwu, M.D., Joshua Stein, M.D., M.S., Paul Lee, M.D., J.D., Thomas Gardner, M.D., M.S., Alan Sugar, M.D., Michael Smith-Wheelock, M.D., Shahzad Mian, M.D. *This report covers the period July 1, 2011, through June 30, 2012
EDUCATION AND GLOBAL REACH
10 Residents make the connection
between research and clinical care
13 Advancing vision care world
wide through collaboration with our global partners
22 New initiatives spark innova-
tion and foster interdisciplinary collaboration across U-M
23 Our faculty join a new
Institute created to improve health care delivery and access
16 Building a model to share
24 Grandnieces of Horace
18 Expanding clinical research
26 Kellogg’s new Taubman
the expertise of specialists in inherited eye disease
to evaluate new treatments
19 How often do patients with
glaucoma need testing? A new tool could help.
20 New training grant will increase the pool of clinician-scientists
and Mary Rackham pay tribute to Kellogg cornea specialist
Scholars are recognized for innovative, treatment-driven research
Dear Friends, At what promises to be a time of significant change—and thus opportunity— in health care, research, and education, I am heartened by the spirit, energy, and values of our “Michigan family.” In this Annual Report, we are proud to highlight the achievements of our faculty, trainees, and staff during the past year. We are also pleased to share with you some of our new initiatives that will help catalyze changes to meet national and global health care needs. We believe that these examples of new approaches to how we work will not only fundamentally enhance our knowledge of science and improve our care for tomorrow’s patients but also empower all of us to realize a better future in which we can truly cure or prevent visual disability. The Department’s vision care initiatives hold great promise because they reflect the guiding principles we all strive to honor: integrity, caring, innovation, and teamwork. In addition, the stories behind the articles in this report—representing the perspectives of our patients, faculty and staff— Paul P. Lee, M.D., J.D. demonstrate how we try each day to integrate these enduring principles into our work. In fact, it is through stories about our experiences at Michigan that we know we are moving in the right direction. Your stories are part of the Michigan and Kellogg experience as well. If you have one you’d like to share, please send it to me at email@example.com. As a graduate of the University of Michigan School of Literature, Science, and the Arts and the Medical School, my experience and stories reflect the strengths of our University and show why I am so confident that the future is bright. Michigan’s support for individual passion and opportunities to work across disciplines was evident during my student years; this dedication has only grown stronger with time. Future achievement will be built on multidisciplinary teamwork in research, education, and clinical care. Our faculty, trainees and staff have embraced this approach, as you will see through stories of our work with the College of Engineering, School of Public Health, the new Institute for Healthcare Policy and Innovation, and international colleagues. We look forward to forging even more partnerships here and around the world. Michigan’s greatest story is about our people: our alumni and friends, faculty and staff, patients and students, and those we ask to join us in creating the future. From great mentors, starting with Paul Lichter, the Department’s longtime chair, I have been fortunate to learn that our obligation is not to repay their kindness but instead to pass their wisdom to others—our colleagues, residents, and fellows—to realize the better future that we all seek. On behalf of the Kellogg family, I thank all of you who have so generously provided support toward our shared goal of preserving vision and improving the lives of our patients.
Paul P. Lee, M.D., J.D. F. Bruce Fralick Professor and Chair University of Michigan Department of Ophthalmology and Visual Sciences Director, W.K. Kellogg Eye Center
“The third function of institutions of higher learning is the creation of wisdom in our students, trainees, staff, and faculty. Wisdom is the multidisciplinary integration of knowledge and experience resulting in the development of new insights — the innovations that improve our understanding of the world and our ability to improve lives.” — Paul P. Lee, M.D., J.D.
Curing, preventing, and treating eye disease The Kellogg Eye Center has always upheld the values of exemplary patient care and dedication to our patients and their families. Kellogg faculty and staff together have developed a statement of purpose, a longterm vision, and a set of guiding principles that reaffirm these values.
Purpose: Improve lives through curing, preventing, and treating eye disease Vision: We seek to improve lives around the world by enhancing vision Guiding Principles Teamwork: We are a collegial, productive, and collaborative community Caring: We are respectful and compassionate Innovation: Our curiosity drives innovation and the quest for knowledge Integrity: Our ethics are built on openness, honesty, and trust
The Chair’s Perspective
Wisdom and the Future
Paul P. Lee, M.D., J.D.
care in the United States and abroad as societies around the world age. In the face of these and other issues, we should remind ourselves that innovation has resulted in the unprecedented progress of the last 100 years and will continue to be the key to better eye and health care. Our focus at Kellogg will not change: to provide our patients with the highest level of care. We seek to continuously implement the best and latest research and to create and refine new models for the delivery of care so that we may improve the lives of patients through the treatment, cure, and prevention of eye disease. What are some of the steps Kellogg is taking toward a better eye and health care system for tomorrow?
University of Michigan Provost Philip J. Hanlon, Ph.D., has noted that institutions of higher learning traditionUnderstanding the “why” of diseases will enable us ally have three functions. The first is the transmission to create new therapies. Recent work on inflammatory of information—the passing on of facts and discrete pathways and early disease manifestations suggest new bits of data. Today, to varying degrees, information is avenues of treatment for diabetic retinopathy and openfree and readily accessible on the internet. The second angle glaucoma that complement existing modes of function is the development of knowledge—of organiztherapy. Discoveries in thyroid eye disease mechanisms ing facts into coherent frameworks are anticipated to lead to new clinical and perspectives. Knowledge is also “Our passion for wisdom trials for thyroid eye disease within increasingly available through the the next year. will drive the successes of internet in ways that both resemble Accelerating the pace of research and complement the offerings of tomorrow and will give that will have a direct impact on the traditional university. The third patient care will make these treatfunction, to which the University of us reason to be optimistic ments available sooner. Across our Michigan is dedicated, is the creation campus, Michigan is a leader in many of wisdom in our students, trainees, about the future, despite areas of translational research. One staff, and faculty. Wisdom is the multhat holds great promise is persontidisciplinary integration of knowlthe challenges we face.” alized medicine, which integrates edge and experience resulting in the many current concepts about disease. development of new insights—the — Paul P. Lee, M.D., J.D. Better understanding of the relationinnovations that improve our underships among genes associated with eye disease, potential standing of the world and our ability to improve lives. environmental factors, and clinical observations brings At Kellogg, our passion for wisdom will drive the us closer to not only assessing a patient’s risk for a parsuccesses of tomorrow and will give us reason to be ticular disease, but also to targeting treatments to the optimistic about the future, despite challenges such as individual’s profile. Similarly, new approaches to clinical empowering access to quality eye care for all; providing research and trials will play a key role in speeding the care with more limited resources while improving qualavailability of new therapies. Our faculty have formed ity; mitigating the growing epidemic of diabetes and the companies to accelerate the movement of the discoversuffering of individuals with multiple health conditions; ies they have made in the lab to patient care settings. and meeting the growing demand for eye and health 4
university of michigan kellogg eye center
Kellogg’s leadership team: Paul Lee, M.D., J.D., Thomas Gardner, M.D., M.S., Alan Sugar, M.D., Michael Smith-Wheelock, M.D., Shahzad Mian, M.D.
Developing our technological expertise will enable us to develop new systems for creating care that are truly patient- and family-centered. In collaboration with the U-M College of Engineering, Kellogg faculty and staff are developing a computer model that will allow physicians in remote locations to tap the diagnostic expertise of a small number of specialists in inherited eye disease. Such a tool could help patients around the world receive emerging treatments for these rare dystrophies. Our faculty have also developed an instrument that might one day be easily used by non-specialists to detect diseases like diabetic retinopathy and macular degeneration long before the first symptoms appear. Health services research is a burgeoning field that brings together experts from many disciplines to ensure that patients can access the right care at the right time. Many faculty in this Department and the University are engaged in initiatives to improve the use of care by populations of individuals who are not receiving adequate care. Other studies seek to identify how to improve outcomes—how patients fare—after being treated with certain medications or procedures. Our potential for solving problems through these kinds of studies is greatly increased by the creation of the Institute for Healthcare Policy and Innovation that brings together over 400 of Michigan’s top health care researchers. Taking the time to ask “why?” and to question our assumptions will drive our continuous quest for wisdom. Asking what we can learn from other industries
and borrowing the best from among ourselves and others will be critical. Among physicians and trainees, we can encourage curiosity and innovation and resist the reflexive response to do things the same way “because we’ve always done it that way.” Forming new structures adapted to the workforce of tomorrow will enable us to leverage new technologies to enhance teaching and patient care. Collaborative, interactive learning will prepare our trainees for the very different health care environment they will work in as leaders of teams. We have also structured a leadership team at Kellogg (see photo) that integrates the strengths of our faculty to create a joint vision for what we hope to accomplish. Keeping our focus on the patient will be our guide. How can we provide care that is faster, more accessible, and less demanding in terms of time and costs? How can patients participate in their own care to the extent they wish to be involved? These and other questions frame our opportunities. As we adapt to meet the challenges of our time, our traditional values and our passion for improving our patients’ lives will not change —but the way we achieve our goals will change. It is our responsibility to think about, encourage, and implement collaborative and innovative ways of improving our systems for delivering health and eye care. By so doing, we honor our responsibility to generate the wisdom that will guide the next generation in their quest for a brighter future. Innovation in vision
â€œLeaders and Bestâ€? in Ophthalmology Patient Visits to the Eye Center The Kellogg Eye Center has enjoyed steady growth, thanks, in part, to the recent opening of our new facility with expanded
space for patients needing clinical and
surgical care. The new space has allowed us to recruit additional faculty who are
developing innovative and treatment-directed programs for patients suffering from debili-
tating eye disease. The Department continues to attract important federal grants and this
year achieved a ranking of #5 in funding awarded to departments of ophthalmology by the National Institutes of Health. 36,853
Funding from the National Institutes of Health
2012 Number 5
2009 Number 15
2011 Number 8 2010 Number 10
Surgical Procedures Performed
2008 Number 10
It Takes a Team How one patient benefited from a multidisciplinary approach to Graves’ eye disease Ester M. Skutt, of Holt, Michigan, remembers vividly the day she was diagnosed with Graves’ disease in October 2009. “I was frightened,” says the former nurse. “I knew it was a pretty bleak situation. I had Terry Smith, M.D., Monte Del Monte, M.D., and Raymond Douglas, M.D., Ph.D., taken care of patients with the disease.” A complex coordinated care for their patient Ester Skutt autoimmune disorder, Graves’ disease results in the overproduction of thyroid hormones, or hyperthyroid To help patients like Ms. Skutt receive expert care ism. The condition affects over 3 million Americans. for this complex condition, the Kellogg Eye Center has One year later, in December 2010, Ms. Skutt develformed its Thyroid Eye Disease Center, which brings oped a cluster of “blisters” on her eyes. “I knew that together specialists from multiple disciplines to provide with Graves’ disease there was a possibility that my eyes integrated care for individuals with thyroid disorders. could be involved,” she says. Her greatest fear was that Surgeons from Kellogg’s oculoplastics service are at the her symptoms could be related to Graves’ eye disease, core of the Center, coordinating a complication that results in clinical care as well as participatswelling of the eyelids, a con“Our office serves as a desing in research aimed at discoverstant stare, eyelid retraction, and ing new therapies for Graves’ and double vision. Left untreated, the tination for patients with thyroid disorders. disorder can lead to permanent In the months that followed, Graves’ eye disease. With vision loss. Ms. Skutt underwent orbital Ms. Skutt’s ophthalmologist one appointment, Ms. Skutt’s decompression surgery to move in nearby Lansing started her on her eyes back into place followed a regimen of steroid therapy to care was consolidated and she by surgery to correct her double address the blistering. After two vision. “It was a terrific team efdoses and strong drug intolerhad a rapid treatment plan.” fort,” she says. “I saw specialists ance, she found herself in the in orbital surgery, strabismus, and hospital with atrial fibrillation, an — Raymond S. Douglas, M.D., Ph.D. endocrinology at Kellogg—and a irregular heartbeat often associspecialist in rheumatology at the ated with congestive heart failure. University of Michigan Health System. The communicaDays later, she was referred to Kellogg’s Raymond S. tion between doctors was fantastic.” Douglas, M.D., Ph.D., a specialist in Graves’ eye disease Dr. Douglas’ office serves as a destination for and renowned orbital, facial plastic and reconstructive patients with Graves’ eye disease. “If Ms. Skutt had to surgeon. go through the normal referral channels, it would have “Ms. Skutt’s inflammation and eye bulging had been months of delay and time lost,” says Dr. Douglas. progressed rapidly and she was beginning to lose “With one appointment, her care was consolidated and vision,” says Dr. Douglas. “Given her intolerance for she had a rapid treatment plan.” steroids, we felt it would be reasonable to try alterna Ms. Skutt has returned to her normal life. “I’m tive anti-inflammatory therapies in conjunction with the doing fantastic,” she says. “My eyes look better than care of a team of rheumatologists. After two infusions, they did before I was diagnosed with Graves’ disease. her disease regressed and we were able to stabilize her The whole experience was just unbelievably good.” thyroid function. Most of her pain also ceased.” Innovation in Patient care
Charlotte Bush, at left, and with her mother, Amanda Bush, who was a patient of Paul Lichter, M.D.
Like Mother, Like Daughter A rare inherited eye disease brings a mother and daughter to the Kellogg Eye Center for treatment Charlotte Bush was just two years old when she made her first trip to the University of Michigan Kellogg Eye Center in 2009. A new experience for the toddler, such visits were more than familiar to her mother, Amanda Bush, of Marshall, Michigan, who has been treated at Kellogg for nearly 33 years for a condition known as Axenfeld-Rieger (A-R) syndrome—an inherited disease that predominantly affects the development of the eye. Ms. Bush suspected Charlotte might have the same disease and, if so, wanted to have it diagnosed and treated promptly; fifty percent of those with the disorder suffer from glaucoma. “Ever since I was a baby, I’ve been coming to Kellogg—it was just a normal part of my life,” says Ms. Bush. “And, I’ve always had great experiences so it was natural to bring my daughter here.” Unfortunately, the mother’s keen instincts proved correct. At Charlotte’s first appointment she was diagnosed with A-R by Paul R. Lichter, M.D., a highly respected glaucoma specialist and former Chair of the Department—and Ms. Bush’s childhood doctor. Once Charlotte’s vision and intraocular pressures were stabilized, she returned to her local ophthalmolo-
university of michigan kellogg eye center
gist for routine check-ups. All went well until Charlotte failed a pre-kindergarten vision screening during the summer of 2012. When Ms. Bush took her daughter to the ophthalmologist to be fitted for eyeglasses, the pressure in her left eye was again elevated and it was recommended that she return to the Kellogg Eye Center. This time, Charlotte was seen by pediatric glaucoma specialist Brenda L. Bohnsack, M.D., Ph.D., who adds her expertise to that of two other faculty who are nationally recognized in pediatric glaucoma, Dr. Lichter and Sayoko E. Moroi, M.D., Ph.D. Dr. Bohnsack decided on surgery to place a glaucoma drainage tube in Charlotte’s left eye so that fluid build-up could be drained off the eye. “The pressure in both of Charlotte’s eyes was elevated, but the left eye showed signs of damage from the glaucoma,” says Dr. Bohnsack. At Charlotte’s one-month check-up, the pressure in her left eye was controlled, but her vision remained somewhat reduced to 20/50 after sustaining vision loss due to the glaucoma. With 20/20 vision in her right eye, she was doing fine visually, but Dr. Bohnsack decided to treat that eye with drops to control the pressure before Charlotte experienced loss of vision. In the future, Dr. Bohnsack anticipates Charlotte may need surgery on the right eye as well. In the meantime, Charlotte will be examined every few months to keep the eye pressure in check. Long term, she has a good prognosis. “In these types of cases, we look at how her mother has lived with the disease, and she has done well,” says Dr. Bohnsack. “This is a good indicator of how Charlotte will do.” Ms. Bush reports that Charlotte has handled surgery and subsequent follow-ups very well.
Brenda Bohnsack, M.D., Ph.D., with patient Charlotte Bush who, like her mother, has Axenfeld-Rieger syndrome.
“Coming to Kellogg’s new pediatric eye clinic has been a good experience for Charlotte. She even asks when we can come back,” says Ms. Bush. “As for Dr. Bohnsack, she is a wonderful doctor who knows how to put Charlotte at ease.”
easily between the clinic and laboratory with a clear sense of how her research will benefit her patients. She believes that understanding how the eye develops will shed light on the cause and possible prevention of congenital eye diseases. Dr. Bohnsack studies the function of genes that are important for the proper development of the front portion of the eye. “Zebrafish serve as a wonderful model because their embryos are transparent, allowing us to see development of the visual system as it happens,” she explains. She works closely with Alon and vision development research Kahana, M.D., Ph.D., whose study of zebrafish focuses on the use of stem cells to regenerate eye tissue lost to The Kellogg Eye Center and Carls Pediatric Ophthalinjury or disease. mology Clinic have a longstanding reputation for excel Dr. Bohnsack is joining an area of research that lence in children’s eye care. Established in 1985 when has been supported for many years by senior scientists Monte A. Del Monte, M.D., joined the Eye Center and Peter F. Hitchcock, Ph.D., and Philip J. Gage, Ph.D. was named the Skillman Professor of Dr. Hitchcock’s laboratory investigates As a clinician-scientist, Pediatric Ophthalmology—the first the function of molecules that govern endowed chair for pediatric ophthaldevelopment of the embryonic retina Dr. Bohnsack has a clear mology in the world—the Service and the capacities of intrinsic stem now widens its scope with the addicells in the adult retina. This work sense of how her research tion of two new subspecialists: Cagri also utilizes zebrafish as a model. G. Besirli, M.D., Ph.D., in pediatric will benefit her patients. Dr. Gage’s laboratory studies mammaretina, and Brenda L. Bohnsack, lian models of congenital eye diseases M.D., Ph.D., in pediatric glaucoma. and glaucoma, including AxenfeldRieger syndrome, with the aim of further understanding These new faculty members join some 15 Kellogg the developmental events that lead to these diseases and physicians in providing children’s eye care throughout eventually developing better treatments. the Eye Center. Now, Dr. Del Monte, along with oculoplastics surgeon Christine C. Nelson, M.D., plans to Though they take different approaches to study create a center for visual development and pediatric eye the development of vision, these Kellogg researchers disease to integrate both the clinical care for children have a common goal: to make scientific discoveries that and our research across the Michigan campus. will improve care today and will cure and prevent eye As a clinician-scientist, Dr. Bohnsack navigates disease in the future.
L i n k i n g children’s eye care
Innovation in Patient care
Kellogg and its residents reap the rewards
“My goal is to ensure that patients not only have access to eye care but that they also receive the proper treatment for their condition.” — Kristen Harris Nwanyanwu, M.D., M.B.A.
Kristen Harris Nwanyanwu, M.D., M.B.A.
Third-year resident Kristen Harris Nwanyanwu, M.D., M.B.A., earned an M.B.A. because she wanted to understand the business side of the health care system. The degree would provide the tools needed to help her fulfill her passion: helping people get the health care they need. It is this passion that led her to work with diabetic retinopathy specialist Thomas W. Gardner, M.D., M.S., and health services researcher Joshua D. Stein, M.D., M.S., on a project investigating factors that influence the progression of diabetic retinopathy, a complication of diabetes caused by changes in the blood vessels of the retina. The project involved examining medical claims from a large health care database in hopes of finding factors—such as hypertension, age, gender, duration of disease, and socioeconomic status—to determine a “score” that could help predict a patient’s risk for
university of michigan kellogg eye center
developing diabetic retinopathy. Clinicians could then use this score as a tool in identifying and treating their high-risk patients as well as motivating them to change behaviors and reduce risk factors. During the second year of residency, Kellogg offers a research rotation that can be completed at the Eye Center or at any other institution in this country or around the world. Dr. Harris Nwanyanwu began her project during her first year and used the rotation to design, research, and write a grant. “The research rotation helps residents build something and see it to fruition,” says Dr. Harris Nwanyanwu. “We have the opportunity to learn about design protocols and research models, as well as writing the grant and navigating the application process. The rotation also allows us to see the value of collaboration within Kellogg and with other parts of the University.” Dr. Harris Nwanyanwu plans to join an academic medical center after completing a retina fellowship. “My goal is to ensure that patients not only have access to eye care but that they also receive the proper treatment for their condition,” she says.
of the research rotation
When second-year resident Ira H. Schachar, M.D., began his residency, he was pleasantly surprised that so many members of the Kellogg faculty wanted him to be involved in their research. He opted to work on a project with retina specialist Thiran Jayasundera, M.D., and ocular pathologist Victor M. Elner, M.D., Ph.D., to quantify fundus autofluorescence (FAF) in age-related macular degeneration (AMD). FAF is an imaging method that targets the retinal pigment epithelial (RPE) cells—cells under the retina that nourish the rods and cones—and yields a higher detection rate for changes associated with vision-threatening diseases like AMD. FAF provides a topographic map of accumulated lipofuscin, the aging pigment, within the RPE. Normal accumulation of lipofuscin occurs with age, but accumulation is more pronounced in AMD. Lipofuscin will produce the majority of FAF Ira Schacher, M.D. when excited by blue light, and FAF that is emitted can recently presented this research at a national retina be digitally recorded and analyzed. conference, he received an enthusiastic response. “Some During his second-year research rotation, Dr. researchers wanted to share their images with us so they Schachar designed a method for quantifying the severity could be analyzed,” says Dr. Schachar. of disease seen in FAF images. By using a novel image “This research is a hot topic in ophanalysis technique, it was possible to “The project has helped thalmology, and the project has allowed compare and quantify differences and me to tap into the scientific community changes in FAF images. This quantificame learn the value of much sooner than I would have othertion process yields a single value—the wise,” he adds. “The project has also Index of Retinal Autofluorescence— collaboration very early helped me learn the value of collaborawhich can be used to assess AMD tion very early in my career.” severity and its change over time. in my career.” Dr. Schachar presented his research “Until this Index was developed, at the Michigan Society of Eye Physiwe did not have a quantitative tool — Ira H. Schachar, M.D. cians and Surgeons’ annual conference for analyzing FAF images,” says Dr. in the summer of 2012. “After speaking with physicians Schachar. “With the help of Dr. Jayasundera and Dr. at the conference,” he says. “I realized how academic Elner, we designed an algorithm and took this project research can help clinicians in private practice.” from ground zero to a point where we could create a pilot study,” says Dr. Schachar. When Dr. Jayasundera
Innovation in Education
Kellogg Senior Scientist Named Associate Dean at Rackham Graduate School
Peter Hitchcock, Ph.D.
Peter F. Hitchcock, Ph.D., Professor, Ophthalmology and Visual Sciences and Professor, Cell and Developmental Biology, has been appointed as an Associate Dean for Academic Programs and Initiatives at the University of Michigan Rackham Graduate School. He will serve the Dean of Rackham for the next four years toward the goal of ensuring excellence in graduate education at the University of Michigan. In his new role, Dr. Hitchcock will undertake two broad tasks. The first is to provide administrative oversight for thirty-one Ph.D. and M.S. graduate programs in the biological, biomedical, and health sciences. The second is to direct initiatives and help craft policy decisions that impact graduate education at the University of Michigan.
During his tenure at Rackham, Dr. Hitchcock will continue to direct his NIH-funded laboratory, which investigates the molecular mechanisms governing early development of the vertebrate retina and stem-cell-based neuronal regeneration in adult nervous tissue. Throughout his career, Dr. Hitchcock has also been dedicated to graduate and postdoctoral training at Michigan. In addition to current and past trainees mentored in his laboratory, Dr. Hitchcock was a former director of the U-M Neuroscience Graduate Program, founding director of the Office of Postdoctoral Studies at the U-M Medical School, and currently serves as director of U-M’s Vision Research Training Grant. Among the many honors Dr. Hitchcock has received are the William and Mary Greve International Research Scholar Award, the Research Sabbatical Award, and the Senior Scientific Investigator Award from Research to Prevent Blindness. He has also received a Fogarty Senior International Research Scholar Award from the National Institutes of Health.
Medical Innovation Fellows to Develop “Telehealth” Concept Four fellows from the U-M Medical Innovation Center (MIC) are stationed at Kellogg during the 2012–13 academic year in hopes of finding ideas that have potential for commercial development.
The fellows have been on-site since July learning about Kellogg and
the field of ophthalmology. They’ve met with personnel from Kellogg’s clinics, labs and satellite offices, have shadowed physicians during patient appointments, and have observed surgeries from the operating room.
“It is important for us to know ophthalmology and be immersed in the
culture at Kellogg,” says fellow Marius Tijunelis, M.D., M.B.A. (at left). “Although one year is a tight timeline, our team hopes to reach the goal of discovering a true need, developing a solution, and starting the commercialization process.”
In the fall, the fellows narrowed their list of 10 ideas to 3 and pre-
sented them to a group of MIC advisors who helped the group select one concept. The fellows are finalizing an idea related to telehealth to improve patient care.
H. Kaz Soong, M.D., Donna Donato, Jonathan Trobe, M.D.
Global Vision The Center for International Ophthalmology is advancing clinical care, education, and research worldwide Ophthalmic disease knows no boundaries. Worldwide, complex eye diseases—from glaucoma to age-related macular degeneration to cataract to diabetic retinopathy—steal the sight of millions of children and adults every year. According to the World Health Organization, more than 285 million people are significantly visually impaired and, of these, 246 million have low vision and 39 million are blind. Uncorrected refractive errors remain the major cause of visual impairment. To solve the puzzles of blinding eye disease, Kellogg clinicians and scientists have long believed that collaboration with our global partners—in clinical care, research, and education—is central to the discovery of new treatments and cures that will improve the lives of patients here and abroad.
To this end, every year our faculty travel the globe with one objective in mind—to participate in the exchange of knowledge about ophthalmology and vision sciences. And we leave our doors wide open to welcome our partners and peers from eye centers and health care institutions—from Beijing to Copenhagen to New Delhi—to do the same. In the past year, Kellogg faculty have led educational courses on Graves’ eye disease in Guangzhou, China; on neuro-ophthalmology in Zurich, Switzerland; and on specialized uses of contact lenses in Shanghai and Taipei. Our clinicians also regularly participate in mission trips to provide basic eye care and surgical care to patients around the world. “We want to learn from others. And we want Innovation in Education
H. Kaz Soong, M.D., Paul Lee, M.D., J.D., Aravind Srinivasan, M.D., Israel Gnanaraj, and Paul Lichter, M.D., after a presentation by Dr. Srinivasan.
Christine Nelson, M.D., speaking with oculoplastic surgeons from China during a tour of the Kellogg Eye Center.
as good as ours in this country and we can learn from others to learn from us,” says Jonathan D. Trobe, their experience.” M.D., Professor, Ophthalmology and Visual Sciences, and Professor, Department of Neurology. “We believe Since this visit, Kellogg faculty and staff have travthat it’s not a one plus one equals two, but a one plus eled to Aravind. Department Chair Paul P. Lee, M.D., one equals ten when we all get together—because J.D., participated in a strategic planning session for everyone has different expertise to share.” the Glaucoma Society of India hosted by Aravind. He Expanding partnerships are highlighted by a June, also visited several sites within the eye care system. 2012, visit to the Kellogg Eye Center by Dr. Aravind “The Aravind system is a remarkable realization of Dr. Srinivasan, administrator of the internationally Venkataswamy’s vision to provide high quality eye care acclaimed Aravind Eye Hospital in to all and to eliminate needless “We believe that it’s not a Madurai, India, and a graduate of blindness,” says Dr. Lee. “We hope the U-M Ross School of Business, to establish greater relationships one plus one equals two, but along with his architect, Israel with Aravind as part of Michigan’s Gnanaraj. Dr. Srinivasan is also the expanding global health mission.” a one plus one equals ten grandson of Aravind founder Dr. Growing collaborations beG. Venkataswamy. In preparation tween Kellogg and its international when we all get together — for an expansion of their operating partners have led to the formation facilities, Dr. Srinivasan and because everyone has differ- of a new platform—the Center for his team were eager to learn from International Ophthalmology, a coKellogg’s experience. Paul R. ordinating agency for interchanges ent expertise to share.” Lichter, M.D., who served as Chair between ophthalmologists and during the recent expansion of the vision scientists here and abroad. — Jonathan D. Trobe, M.D. Eye Center, led the Aravind team The Center is part of a larger on a tour of Kellogg’s state-of-the-art surgical suites. network of international initiatives under the University “The Aravind Eye Care System is unique,” says of Michigan Global Reach program. “We have our own H. Kaz Soong, M.D., Professor, Ophthalmology and projects and creativities,” says Dr. Trobe. “Yet we are integrated with the U-M Global Reach program, which Visual Sciences. “The System, which encompasses 11 seeks to unify all efforts across campus.” hospitals throughout India, performs 900 to 1200 ocular surgeries a day. Their complication rates are
university of michigan kellogg eye center
Sherry Day, O.D., top row, second from right, in Migori, Kenya with colleagues from Henry Ford Hospital and the University of Michigan Health System on a ten-day trip sponsored by Kenyarelief.org
Raymond Douglas, M.D., Ph.D., with Fengyuan Sun, M.D., Tianjin, China
Inspiring Innovation New Resident Career Development Grant The Department of Ophthalmology and Visual Sciences has initiated the Michigan Ophthalmology Trainee Career Development Award, a new academic grant program that encourages residents and trainees to pursue projects they are passionate about. Recipients of the award select faculty at Kellogg and throughout the campus to partner with them in accomplishing their goals. Since its inauguration, two grants have been awarded to Kellogg residents. Crandall E. Peeler, M.D., second-year resident, will travel to Bhairawa, Nepal to evaluate whether a lowcost automated fundus camera can improve screening efforts in rural areas. A central question in his project is whether health care workers with little training in ocular photography can use the portable camera to capture high-resolution fundus photographs used to diagnose eye disease. His goal is to help remote clinics identify patients who should be referred to larger medical centers where higher level care for eye disease is available.
Crandall Peeler, M.D.
Abigail Fahim, M.D., Ph.D.
Abigail T. Fahim, M.D., Ph.D., also a second-year resident, received grant funding for her research in X-linked retinitis pigmentosa (XLRP), an inherited blinding disorder of the retina. Dr. Fahim is working to understand how lyonization, a process in which one X chromosome is silenced in every cell of a womanâ€™s body, affects disease severity in women who carry a mutation for XLRP. All residents and trainees are eligible to apply for the award, and proposals are reviewed by the Kellogg Research and Therapeutics Committee.
Innovation in Education
Sharing the Expertise A computer model could help more patients know which genes — and emerging treatments— a r e linked to their retinal disease Specialists in inherited retinal diseases—rare eye conditions that often lead to blindness or near blindness— are few and far between. Yet these physicians offer their patients a great deal of hope by identifying complex conditions and then confirming the diagnosis with genetic testing. To share the expertise of this small group of retina experts, Thiran Jayasundera, M.D., a specialist in retinal dystrophy at the Kellogg Eye Center, is collaborating with faculty from the U-M College of Engineering. Together, they plan to create a computer model, RetDegenDx, to help physicians arrive at a diagnosis for their patients—the first step in finding treatments for uncommon retinal diseases.
The Kellogg Eye Center is a natural starting point for such a system. John R. Heckenlively, M.D., the Paul R. Lichter Professor of Ophthalmic Genetics, has kept genetic profiles of his patients for years, creating a rich collection of clinical observations linked with genetic tests confirming the causative gene or genes. “It’s still very early in the development process,” observes Dr. Jayasundera, who completed a fellowship with Dr. Heckenlively before joining Kellogg’s faculty. “But we know that data like this could help direct at least a small group of patients to the correct therapeutic trial.” The engineering team will develop image recognition software to identify indicators of disease that a specialist like Dr. Jayasundera would readily see in
Kellogg’s retinal dystrophy team includes physicians, genetic counselors, and research scientists. Back row: Sarwar Zahid (medical student), Jillian Huang, M.S., David Zacks, M.D., Ph.D., Kari Branham, M.S., C.G.C., Naheed Khan, Ph.D. Front row: Debra Thompson, Ph.D., John Heckenlively, M.D., Thiran Jayasundera, M.D.
university of michigan kellogg eye center
Dr. Jayasundera is also involved in a new study on Stargardt’s disease.
scans of his patients’ retinas. Added to the data are everywhere have a chance to learn about trials profiles of individual patients with confirmed diagnoses, that could benefit them,” he says. “We hope that including the causative genes that have been identified. RetDegenDx is the tool that links patients with the As the tool grows with confirmed cases, it would allow treatments that can target their specific conditions.” another physician to enter a retinal scan and clinical data, triggering a search for near matches. In the best case, the physician would receive a probable diagnosis Tracking the progression of and a “short list” of genes to be tested. Besides offering patients and doctors a faster diagnosis, RetDegenDx has economic advantages. Genetic testing is costly, and few clinics can afford the time Learning about the progression of a disease may help or expense of testing for more than a few “suspect” researchers develop new treatments or direct patients genes among the 185 that have been identified in retinal to clinical trials. Thanks to a grant from the Midwest diseases to date. Eye-Banks, Dr. Jayasundera and his “Developing this type of scan team will monitor the vision of a “As new therapies are recognition, combining it with clinigroup of Kellogg patients affected discovered, we want to cal data, and creating a diagnostic by Stargardt’s disease, an inherited tool is a straightforward engineering eye disease that affects children and make sure that patients problem,” says Gail Hohner, Manyoung adults, and results in the loss aging Director of the U-M College of central vision. everywhere have a chance of Engineering’s Multidisciplinary Compared to macular degeneraDesign Program. “Our engineertions that affect adults, Stargardt’s to learn about trials that ing students will be part of a team progresses at a relatively fast pace. developing algorithms to identify Using an analysis algorithm develcould benefit them.” patterns and make predictions from oped at the Kellogg Eye Center, the a wide range of variables,” she research team hopes to track the — Thiran Jayasundera, M.D. says. “Because the system improves stages of vision loss at an earlier point as more data are entered, the key is to collect as many in the disease than is now possible. cases as possible from clinics across the country.” “This study should help us understand how young patients with similar characteristics will progress over Dr. Jayasundera observes that a few clinical trials time,” says Dr. Jayasundera. “That information could for retinal dystrophies are beginning to emerge with tell us who might benefit from therapies on the horizon gene therapies and stem cell treatments. “As new theraor in newly emerging clinical trials.” pies are discovered, we want to make sure that patients
Innovation in Research
Highlighted studies and trials at Kellogg: Dr. Comer is currently recruiting volunteers for a two-year observational study to investigate functional and structural changes to the retina before and after treatment with anti-VEGF agents. His goal is to determine the source of vision loss in macular edema, a condition in which leaking blood vessels cause swelling of the retina. Victor M. Elner, M.D., Ph.D., and his team are using novel non-invasive imaging he developed in 2008 to assess severity and treatment of juvenile diabetes and age-related macular degeneration. These Grant Comer, M.D., M.S., is helping to lead Kellogg’s clinical research initiative. diseases are traditionally evaluated only by alterations in vision or ocular structure that occur late in the disease and only slowly respond to treatment. The new imaging is being used to assess metabolic status of retinal cells that changes early and rapidly in early disease and after treatment, giving researchers a more effective guide for dealing with these diseases. John R. Heckenlively, M.D., is helping to test whether the compound, valproic acid (VPA), would Kellogg is building a next-generation be a good candidate for treating retinitis pigmentosa center to evaluate new treatments (RP). To date there are no FDA-approved treatments for RP, a group of diseases in which damage to retinal Over the past year, Kellogg researchers and clinicians cells leads to gradual loss of vision and eventual have been laying the groundwork for a new clinical blindness. The trial will collect safety information trials center to meet the needs of patients who seek and will evaluate the ability of VPA to slow or even promising new treatments for eye disease. One of the reverse vision loss from RP. driving forces behind the center is Kellogg has also been awarded Grant M. Comer, M.D., M.S., a a National Eye Institute Clinical “Our patients look to us for retina specialist and the Edward T. Trial Planning Grant to develop and Ellen K. Dryer Career Develop- the latest advances in treatthe infrastructure needed to carry ment Professor. out a large multi-center glaucoma ment, especially when they “Clinical trials allow us to trial. The proposed trial would determine whether promising new evaluate whether statins, a class experience diseases for which of drugs used to lower cholesterol, medications are effective and safe in treating eye disease,” says Dr. could prevent disease progression there are less than optimal Comer. “Our patients look to us among individuals with mild to for the latest advances in treatment, treatments — or none at all.” moderate open-angle glaucoma. especially when they experience disDavid C. Musch, Ph.D., M.P.H., eases for which there are less than and Joshua D. Stein, M.D., M.S., — Grant Comer, M.D., M.S. optimal treatments—or none at all.” will lead the effort. Renovations will soon begin to create a more con Dr. Comer and the clinical research staff are venient setting for research volunteers. The new space optimistic about the impact the center could have on will also accommodate the larger clinical staff needed to improving eye care. “We are hopeful that we can dehelp manage compliance with federal regulations, study velop clinical studies to bring more treatments to more protocols, and increasing reporting requirements. patients on a fast, safe, and effective timeline,” he says.
Focus on Clinical Research
university of michigan kellogg eye center
Joining Forces to Develop a New Diagnostic Tool A computer model could help determine how often to test for progression of glaucoma and other chronic conditions Mark Van Oyen, Ph.D., Mariel Lavieri, Ph.D., and Joshua Stein, M.D., M.S.
How frequently should your ophthalmologist ask you the clinic for testing more often than needed,” says Dr. to undergo testing for glaucoma? The answer is imStein. “And patients can become anxious while underportant because patients with glaucoma who are not going testing, which can lead to unreliable results and seen frequently enough are at risk of losing vision that the need to repeat the test.” cannot be restored. Yet too-frequent monitoring can be The computer model, which projects a personalized a burden for patients. “time for next test,” is novel because it is updated each time a test has been performed. The algorithm is A new computer modeling system could help based on data from large clinical trials in combination physicians—especially non-specialists—predict which patients are likely to remain stable and which are likely with patient information—such as eye pressure and to experience worsening disease over a relatively short visual field test results—that accumulates as more tests time. The patient could then be advised when to return are completed. to the clinic for testing and treatment The research team has filed a patent “Our work is based on based on output from an algorithm. for the model, which has applications beyond glaucoma or even eye disease. The project is a collaboration of foundational systems “An algorithm like this can be applied Kellogg glaucoma specialist Joshua to any chronic disease that requires testD. Stein, M.D., M.S., and epideengineering models that ing over time,” says Dr. Stein. “It could miologist David C. Musch, Ph.D., help physicians manage diabetes and M.P.H., and colleagues in Industrial also allowed us to put high blood pressure, or any condition and Operations Engineering at the requiring repeated measurements.” U-M College of Engineering, includa man on the moon.” The research team has validated the ing Mariel S. Lavieri, Ph.D., and Mark P. Van Oyen, Ph.D. model by testing it against data from — Mark Van Oyen, Ph.D. national clinical studies. One such trial, For specialists like Dr. Stein, the Collaborative Initial Glaucoma Treatment Study, led the model provides one more tool to aid with decision by investigators at the Kellogg Eye Center, provided 10 making. “Technology of this sort is not a replacement years of test results on over 600 patients with newly difor the judgment of the physician,” he says. “But taking agnosed glaucoma. “When we compared our algorithm advantage of computer modeling–based innovations can to currently accepted testing practices represented in the absolutely enhance our diagnostic abilities.” trial, it demonstrated better accuracy and decreased de Over 2.2 million Americans have glaucoma, a leadlay in identifying disease progression,” says Dr. Lavieri. ing cause of visual impairment in the United States and worldwide. Because glaucoma often occurs without “Our work is based on foundational systems ensymptoms, a patient can experience irreversible vision gineering models that also allowed us to put a man on loss before being diagnosed with the disease. Any delay the moon,” says Dr. Van Oyen. “This research will lead in treatment can have significant consequences. to more efficient use of resources with more effective “There are also costs to having patients return to patient care.” Innovation in Research
Kellogg is awarded an nei training grant Kellogg will train clinician-scientists
make the transition from participating in mentored research projects to serving as investigators for indepenunder a new NEI K12 Training Grant dently funded projects. “The K12 grant provides an avenue for the DepartThe Kellogg Eye Center has been awarded a grant to ment to recruit and train outstanding clinician-scienrecruit, train, and mentor ophthalmologists who plan tists,” says Thomas W. Gardner, M.D., M.S., Associate to develop research programs in tandem with their Chair for Research. “We expect to attract candidates clinical practice. Kellogg is one of six ophthalmology who are extremely bright, inquisitive and mindful that departments in the nation to research discoveries arising from have received this award from clinical practice can help us elimi“The K12 grant provides an the National Eye Institute, whose nate preventable vision loss and goal is to increase the number avenue for the Department to improve the lives of our patients.” and effectiveness of clinician Dr. Gardner and Department scientists in ophthalmology and Chair Paul P. Lee, M.D., J.D., will recruit and train outstanding vision sciences. serve as co-principal investigators Newly trained ophthalmolofor the grant. In their proposal clinician-scientists.” gists, who have had years of medithey cited the tremendous re— Thomas W. Gardner, M.D., M.S. cal education, often find it difficult sources of the U-M Health Systo invest additional time acquiring tem, which was awarded $368.7 the skills needed to develop successful research promillion in research grants from the National Institutes grams. Under the grant, Kellogg is recruiting candidates of Health in 2011, as well as the Kellogg Eye Center’s to the Michigan Vision Clinician-Scientist Development research strengths in areas such as retinal stem cells and Program and will provide them with mentoring, proregeneration, diabetic retinopathy, epidemiology and tected time for research, core instruction, and a range of biostatistics, and thyroid eye disease. In 2012, Kellogg skills that will enable them to manage a major research was ranked 5th in NIH funding awarded to departenterprise. The program is designed to help trainees ments of ophthalmology.
Fostering repair processes in
Steven F. Abcouwer, Ph.D., Associate Professor, Ophthalmology and Visual Sciences, has been awarded a National Institutes of Health grant (R01). Under the grant, Bone Marrow Neuropathy Drives Diabetic Retinopathy, Dr. Abcouwer and colleagues at Michigan State University and the University of Florida will study repair processes that may prevent the progression of retinal tissue damage and inflammation that results in loss of sight during diabetic retinopathy. “Our work is based on the observation that 20
university of michigan kellogg eye center
diabetes impedes nerve communication with the bone marrow, which is necessary for the release of stem-cell-derived precursor cells that travel to sites of tissue damage and aid in their repair,” says Dr. Abcouwer. “Previous studies have focused on processes that lead to retinal damage, rather than restoration. This research is significant because it could lead to ways of preventing diabetic retinopathy by fostering the bodies’ own repair processes.”
Steven Abcouwer, Ph.D.
plus Diabetes and glaucoma grants Preventing retinal cell death associated with diabetes Patrice E. Fort, Ph.D., M.S., Research Assistant Professor, recently received a National Institutes of Health grant (R01) for his project, Progressive Impact of Diabetes on Retinal Neuroprotection by Alpha-Crystallins. Dr. Fort is studying how the natural adaptive mechanisms for protection of the retina are impaired by diabetes—which leads to cell death and ultimately loss of vision. “Understanding how the protective abilities of alpha-crystallins [neuroprotective proteins] are affected in disease states will enable us to develop novel approaches to manipulate these pathways and provide therapeutic benefit to preserve vision in persons with diabetes,” says Dr. Fort. “This research is significant because it could lead to the development of new therapeutic strategies for diabetic retinopathy and other chronic retinal neurodegenerative disorders such as age-related macular degeneration.”
Patrice Fort, Ph.D., M.S.
Finding the optimal glaucoma treatment for each patient Sayoko E. Moroi, M.D., Ph.D., Professor and glaucoma specialist, is also a recent recipient of a National Institutes of Health award (R01). Under the four-year collaborative research investigation, Aqueous Humor Dynamic Components that Determine Intraocular Pressure Variance, Dr. Moroi seeks to identify biomarkers associated with fluctuation in eye pressure and variation in response to glaucoma treatment that will make it possible to predict the optimal treatment for each patient. “If there are biomarkers that are linked to a poor response, then we may be able to avoid unnecessary treatment and wasted office visits,” says Dr. Moroi. “Using these profiles to determine in advance the best treatment could have a major impact in preventing the most severe effects of the disease.”
Sayoko Moroi, M.D., Ph.D. Innovation in Research
to Spur Research Two new programs will help fund collaborative research throughout the University
Kwoon Wong, Ph.D., who investigates subconscious vision, sees potential for collaboration with architects on lighting technologies.
Kellogg researcher Kwoon Y. Wong, Ph.D., investigates retinal neurons that drive subconscious physiological Fast Forward to tomorrow’s cures responses to light—such as pupil reflex, the synchroniAnother initiative to support research at Michigan is zation of the sleep-wake cycle with environmental lightthe Strategic Research Initiative—a $100 million comdark cycles, and the modulation of hormone secretion. mitment over three years from the Medical School Dr. Wong believes this research would benefit from Dean’s Office. Its goal is to “fast forward” research collaboration with other departments at the University. around a common vision to develop tomorrow’s cures. “We could partner with architects to study how lighting As a first step, the Health System’s research conditions might influence subconscious vision or with strengths were identified—cancer, inflammation, metaengineers to develop novel lighting technologies that bolic diseases, vascular diseases, and nervous system optimally stimulate these subconscious visual neurons,” disorders. From there, the goal was says Dr. Wong. “But lack of fundto discover opportunities at the ing has been an issue.” “Research in the visual intersections of 10 research strengths, Such collaboration is a reality sciences fits quite naturally including drug development, personthanks to MCubed—a new U-M alized medicine, and aging. program designed to fund pilot at the intersections defined U-M researchers, including studies that spark innovation and 15 Kellogg faculty members, have foster multidisciplinary teamwork. by the Dean’s initiative.” formed interdisciplinary teams to To qualify, researchers form teams develop proposals. Winners will be of three, representing at least two — Paul P. Lee, M.D., J.D. announced in early 2013. disciplines. Funded projects receive “Research in the visual sciences $60,000. fits quite naturally at the intersections defined by the The first 50 projects were selected in November. Dean’s initiative,” says Paul P. Lee, M.D., J.D., Chair Kellogg epidemiologist David C. Musch, Ph.D., M.P.H., and F. Bruce Fralick Professor of Ophthalmology. along with faculty from the Department of Otolaryn“Our faculty are currently working on aging and eye gology-Head and Neck Surgery and the College of Engidisease, drugs targeted at retinal disease, and personalneering, received funding for a project on the potential ized therapies for glaucoma—to name a few areas benefit of using antacids to treat skin cancer of the head that could yield new treatments for eye disease.” and neck. The initiative began with a large investment in Retina specialist Thiran Jayasundera, M.D., and infrastructure, the purchase of the North Campus colleagues from the College of Engineering won funding Research Complex in 2009. The facility, designed to to create a computer model for patients with inherited foster multidisciplinary collaboration among researchretinal diseases (read more on page 16). ers, houses biomedical research core facilities with DNA MCubed plans to select 200 additional projects, sequencing technologies and centralized data storage, as and more than 20 Kellogg faculty members—like well as a biorepository and space for clinical trials. Dr. Wong—are hopeful their projects will be chosen. 22
university of michigan kellogg eye center
Sharing Resources and Collaborating on Tough Health Care Issues 400 health services researchers will
of the U-M Medical School. According to Department Chair work together to make health care and IHPI member Paul P. Lee, M.D., better, safer, and more cost effective J.D., the Institute will tap the expertise of specialists in health care data analyJoshua D. Stein, M.D., M.S., a clinisis, among them Marie Lynn Miranda, cian and health services researcher at Ph.D., Dean of the U-M School of the University of Michigan Kellogg Eye Natural Resources and Environment. Center, uses large health care databases “Dean Miranda has made groundto study utilization patterns and patient breaking use of geospatial mapping in outcomes of eye care in the United health care,” he says. “We are fortunate States. Now, Dr. Stein will have access that her team will be applying those to even more resources—as well as tools to the new W.K. Kellogg FoundaJoshua Stein, M.D., M.S. more opportunities to collaborate with tion grant to improve utilization of U-M faculty and others—as a memeye care services by children throughout ber of the newly created U-M Institute for Healthcare the state of Michigan, especially in disadvantaged Policy and Innovation (IHPI). communities.” Geospatial mapping allows researchers IHPI is one of the nation’s largest communities to visualize data related to the locations of patients, of physicians, scientists, and policy analysts studying patterns of health care, and social and community how health care works and, more importantly, how to resources for a given area. improve it. To date, IHPI is comprised of approximately “Through affiliation and partnerships with other 400 health services researchers at U-M, as well as noncenters and institutes at Michigan, we can begin to profit and private sector organizations. link changes in public policies to “The idea behind IHPI is to gather “We hope to make sub- improvements in the health of people talented individuals from different in Michigan and around the United stantial contributions to States,” adds Dr. Lee. disciplines and university programs and give them the shared space and In addition to Dr. Lee and Dr. Stein, the practice of health support they need to successfully Kellogg is represented by Paul R. Lichter, understand the changing health care M.D., David C. Musch, Ph.D., M.P.H., care and to the health system, advance beneficial healthRoni M. Shtein, M.D., M.S., and fellow related policies, and inform efforts to Paula Anne Newman-Casey, M.D. of our patients.” improve patients’ well-being through “Establishing this institute shows health services research,” says Dr. — Joshua D. Stein, M.D., M.S. U-M’s commitment and dedication to Stein. “Although IHPI members supporting researchers and creating an come from many different departments and programs environment for us to achieve our potential as health throughout the University, we are now positioned to care innovators,” says Dr. Stein. “We now have an pool our resources and learn from one another in a exciting opportunity to come together, share ideas, and highly collaborative environment.” In addition to facullearn from each other. Through our synergy, we hope to ty from the U-M Medical School, IHPI members include make substantial contributions to the practice of health faculty from the U-M School of Public Health, the Ford care and the health of patients here in Michigan and School of Public Policy, and the U-M Institute for Social around the globe.” Research. Founded in 2011, the Institute is an initiative Innovation in Research
Katherine (left) and Joanne (right) Rackham visit the plaque honoring their late uncle in the rotunda of his namesake Horace H. Rackham School of Graduate Studies.
A Legacy of Sight Grandnieces of U-M benefactors Horace and Mary Rackham honor a beloved Kellogg cornea specialist with their bequests to advance ophthalmic research Last year, Joanne Rackham, 81, and Katherine Rackham, 80, of Plymouth, Michigan, grandnieces of U-M benefactors Horace H. and Mary A. Rackham, widened the reach of their extraordinary family legacy with their bequests to the Kellogg Eye Center in support of cornea research. The planned gifts celebrate their special relationship with Alan Sugar, M.D., Professor and Vice Chair, Ophthalmology and Visual Sciences, who has cared for Joanne for over 25 years. The gifts will establish an endowment to support cornea research in perpetuity. “We want Dr. Sugar to have what he needs to do his research. My work and Katherine’s work always meant everything to us, and now Dr. Sugar’s work is 24
university of michigan kellogg eye center
the future we care most about. He will change the world for so many people,” says Joanne. “Dr. Sugar is the greatest guy in the world. He’s been a savior to me. There are people who come along once in a lifetime who are irreplaceable. Dr. Sugar is one of them.” With full agreement and gratitude, her sister Katherine adds, “The man is remarkable.” The sisters’ longstanding relationship with the University of Michigan Kellogg Eye Center began in 1987 when Joanne was diagnosed with Fuchs dystrophy, an inherited corneal degeneration that required her to have a first corneal transplant in her right eye in 1987 and a second in her left eye in 1993. “I would sit in the waiting room and see children and ladies who
Joanne (left) and Katherine Rackham have made plans to establish an endowment for cornea research. Joanne is a longtime patient of Dr. Alan Sugar (right).
endowment for graduate education. At the time it were also dealing with this condition. I wanted to help was the largest gift ever given in support of graduate them. This is something I can do as a service, because education in the United States, and without a doubt I didn’t have any children myself.” Retinal specialist, in the world. Andrew K. Vine, M.D., also assisted in Joanne’s care when she needed treatment for a detached retina. The Rackham Graduate School continues today as Affecting four percent of the population, Fuchs the home of graduate and professional education at the disease destroys the thin layer of cells that line the back University of Michigan and as a major center of cultural part of the cornea and is the leading indication for and intellectual exchange. corneal transplantation. More common in women than Paul P. Lee, M.D., J.D., Chair of the Department of in men, the disorder typically affects individuals in their Ophthalmology and Visual Sciences, says, “Dr. Sugar’s 50s or 60s—although occasionally research has advanced our underappears earlier in adulthood. standing of corneal transplanta“The generosity of the Dr. Sugar admits he was greatly tion and degenerative diseases like Rackham sisters is remark- Fuchs dystrophy. With this gift, Dr. surprised when he learned of the bequests. “The generosity of the Sugar and his team will be able to able. It shows a willingness carry their work forward to have an Rackham sisters is remarkable,” he says. “It shows a willingness to enduring impact on patients who to create a lasting legacy create a lasting legacy that will help suffer from corneal disease. It is a patients for decades to come. I am fitting tribute to one of our most that will help patients for deeply honored.” distinguished and respected faculty members.” The cornea service will use this decades to come.” For the past thirty years, Dr. gift for generations to gain better Sugar has provided a small white understanding of the physiology — Alan Sugar, M.D. card with his office phone number, of Fuchs disease and its genetics, home phone number, and paging number to all his advance surgical techniques, and improve donor cornea surgical patients. “Something as simple as this card preparation and eye banking. “I don’t think that we reflects Michigan’s philosophy of patient-centered care, will end corneal dystrophies and degenerations, but we of thinking what would most help our patients when will lessen the blindness they can cause and improve the they encounter problems, even if it’s in the middle of the lives of those with these conditions,” says Dr. Sugar. night,” he explains. Over the years, Joanne was one of The sisters—and last remaining heirs to carry the many patients who benefited from Dr. Sugar’s uncomRackham name—continue the family legacy in support mon kindness. “One of my girlfriends needed eye care of intellectual exploration that began in 1935 when recently, so I called Dr. Sugar to ask if he accepted refertrustees of the Horace and Mary Rackham Fund gave rals,” says Joanne. “Then I gave her his home phone the University of Michigan $6.5 million for the connumber. She still sees him and is doing very well.” struction of the Rackham Graduate School and an Innovation in vision
focus on translating research into
Dr. Gardner is the Taubman Healthy Eyes Scholar
years from the Taubman Institute’s endowment and JDRF. The JDRF grant is Thomas W. Gardner, M.D., supported by the Ford MoM.S., Professor of Ophthaltor Company Fund as part of mology and Visual Sciences JDRF’s Healthy Eyes Project, and of Molecular and Integraan initiative to ensure that adtive Physiology, has long been vances in retinopathy science recognized for his research are translated into treatments to find novel treatments for for people with diabetes. diabetes-related eye disease. “This research offers Dr. Gardner was named the promise for those facing or first Healthy Eyes Scholar living with blindness caused by the A. Alfred Taubman by diabetes,” says James G. Medical Research Institute Vella, president of the Ford and JDRF, formerly the Motor Company Fund and Thomas Gardner, M.D., M.S., Kate Durak, JDRF, and Paul Lee, M.D., J.D. Juvenile Diabetes Research Community Services. “This Foundation, the leading global investment is made possible by organization focused on type 1 diabetes research. the thousands of Ford employees around the world who JDRF and the Taubman Institute will support a together with Ford Motor Company have raised tens of three-year grant for Dr. Gardner to study novel treatmillions to support JDRF and diabetes research.” ments and biomarkers—indicators that can measure the The collaboration with JDRF marks the first time progress of disease and the effectiveness of treatments an outside organization has co-sponsored a Taubman — for diabetic retinopathy, the most common complicaScholar. “This exciting alliance will make it possible tion of diabetes and the leading cause of legal blindness for us to accept yet another eminent researcher into the among adults aged 20 to 74 years in the United States. program,” says Eva L. Feldman, M.D., Ph.D., Director “Dr. Gardner’s focus on detection of preclinical of the Taubman Institute. “We’re proud of our relationdiabetic eye disease—that is, before individuals or their ship with JDRF and delighted to welcome Dr. Gardner physicians realize that eye function is deteriorating— and his colleagues to our pool of scientists who are would allow people with diabetes to be treated at an working on cutting-edge cures and treatment.” earlier stage of the disease when therapy is more likely “I’m thrilled and honored,” says Dr. Gardner. “We to be effective,” says Helen Nickerson, Ph.D., JDRF’s hope to not only understand what causes retinopathy senior scientific manager of complications. “Validated and how to prevent it, but perhaps even to restore the methods of early detection would also reduce the time vision in patients who have lost it,” he says. “Right needed to conduct clinical trials and speed the developnow we truly have nothing to offer those people, but ment of new therapies for diabetic eye disease.” our goal is to change that. The Taubman Institute likes Dr. Gardner will receive $150,000 for each of three bold and audacious ideas, and we’ve given them one.” 26
university of michigan kellogg eye center
new treatments for eye disease
Dr. Kahana is a Taubman Emerging Scholar
“We believe that regenerative medicine will play a key role in the future of medical care,” says Dr. Kahana. Alon Kahana, M.D., “Our work on eye muscles has identified stem cells and Ph.D., Assistant pathways that could one day be used to facilitate regenProfessor and Helmut eration as therapy for muscle disorders affecting vision, F. Stern Career Develas well as for degenerative disorders such as Duchene opment Professor of muscular dystrophy. In addition, greater understanding Ophthalmology and of the role of stem cells in driving tissue repair versus Visual Sciences, directs scarring could help us develop new approaches to the a research program treatment of complex eye conditions, such as thyroid investigating the use of eye disease.” stem cells to regenerate Karen Davidson will tell you that what struck her eye tissue. Now he has most when she first met Dr. Kahana was his enthusiasm been named the Mrs. for research. “He has such passion to grow our underWilliam Davidson standing of disease and directly affect treatment. If Emerging Scholar by there’s anyone who can do it, he can. And I really hope the Taubman Emerghe does,” says Mrs. Davidson. “My family has been Alon Kahana, M.D., Ph.D. ing Scholars Program personally impacted by the type of orbital eye diseases at the A. Alfred Taubman Medical Research Institute. that Dr. Kahana studies. I want to do what I can to help The Emerging Scholars Program, created to support others who struggle with these diseases—they deserve early career physician-scientists whose laboratory work to have hope. Finding meaningful treatments could aims to translate basic research into significantly improve outcomes new treatments for disease, connects “We believe that regenerative for these patients.” University of Michigan Medical “I’m honored to be the recipimedicine will play a key role School faculty members at the asent of Mrs. Davidson’s trust and sistant professor level with philanin the future of medical care.” generosity,” says Dr. Kahana. thropists who pledge to support “This gift provides the opporthe physicians’ research for three tunity to have an impact on the — Alon Kahana, M.D., Ph.D. years—at $50,000 per year. lives of patients, colleagues, and “We urgently need the best and brightest doctors trainees. And, it connects us with some of the most acwho are motivated by the patient suffering they witness complished scientists and physicians at the University each day to continue to develop new therapies,” says of Michigan. Her belief in our research has motivated Eva L. Feldman, M.D., Ph.D., Director of the Taubman us to work even harder to develop new treatments and Institute. cures to blinding and debilitating diseases. We are very Dr. Kahana’s research focuses on the use of stem grateful to Mrs. Davidson, as well as Mr. Taubman and cells to regenerate eye tissue lost to injury or disease. Dr. Feldman, for their support and leadership.”
Innovation in vision
With gratitude for gifts made from July 1, 2011, through June 30, 2012
Annual Honor Roll of Donors
$10,000 to $49,999
Anonymous Donor The Carls Foundation Arnold and Mabel Beckman Foundation Jerome Jacobson Foundation Edwin E. Meader Estate Joel and Susan Mindel Elsa U. Pardee Foundation Research to Prevent Blindness The Harry A. and Margaret D. Towsley Foundation
American Diabetes Association, Inc. BCBSM Foundation Birkhill Family Foundation Michael and Joanne Bisson Thomas W. Breakey Eric and Sara Conn Sandra and David Detrisac Ruth Dixon Ann S. Edwards Frances and David H. Grossman Richard F. and Susan Gutow Charles S. and Ann S. Hutchins William and Gina Keough Al and Colette Kessel Drs. Vik and Bithika Kheterpal Ronald Kurtz and Jennifer Simpson Carolyn and Paul Lichter Keith and Della McKenzie The Meijer Foundation Larry G. Miller Bruce and Roberta Oliver Gilbert S. Omenn and Martha A. Darling Michael Pachtman Mildred E. Swanson Foundation David and Jayne VerLee Margaret F. Vezina Estate The Honorable Nancy C. Wheeler
$50,000 to $99,999
$5,000 to $9,999
With heartfelt thanks to donors who made gifts from July 1, 2011, through June 30, 2012. Included in this listing are contributors whose donations are part of multi-year pledges.
$500,000 to $999,999 Lynn H. and Robert W. Browne Juvenile Diabetes Research Foundation
$100,000 to $499,999
Anonymous Donors (2) The Foundation Fighting Blindness Lois M. McClain Estate Mickey and Karen Shapiro Timothy and Laurie G. Wadhams
Carol A. Ball Jason M. Burgett, M.D. Don and Betts Chisholm Mark and Judith Cohen Scott M. Corin and Nina Blumenthal
“Generous donor support has allowed us to follow hunches and explore new ideas that are outside the scope of NIH-funded research. This has resulted in exciting discoveries and new avenues of research that otherwise may not have been possible.” — Bret A. Hughes, Ph.D.
university of michigan kellogg eye center
Dow Chemical Company Foundation Michael G. and Deborah L. Harrison Tarek S. Hassan and Diana M. Gomez-Hassan Helen and Richard Kerr Susan J. Lane Corey Miller Carol Standardi Gerald and Joyce Trocchio Danny D. Wang and Yili Wang W. Scott and Jill Wilkinson
$1,000 to $4,999 Anonymous Donors (2) Gerald and Gloria Abrams Anthony and Mary Adamis Amjad Z. Ahmad, M.D. Steven and Carol Archer Dr. and Mrs. Robert C. Arends Everton and Saundrett Arrindell Betty Baier and Mark Kesson Harry and Patricia Bash Anne and Terry J. Bergstrom Rhoda L. and Roger M. Berkowitz Donald and Christine Beser Rohit and Shakti Bhatnagar George F. Blass Eleanor E. Brownell Elizabeth A. Callaway Bruce D. Cameron, M.D. Keith D. and Cheryl D. Carter Janet and Bill Cassebaum Dr. William S. Clifford Paul Cochran Claude M. Coleman Glen Copeland
With gratitude for gifts made from July 1, 2011, through June 30, 2012
“All of us at Kellogg are dedicated to integrating our clinical care, research, and educational missions. Grateful patients and donors are essential in helping us realize our goal of treating, curing, and preventing eye disease.” — Michael W. Smith-Wheelock, M.D.
Assistant Professor Associate Chair for Clinical Affairs
Wayne T. and Barbara M. Cornblath Dr. and Mrs. Morton S. Cox Katherine and Ralph Crew Damon’s Grill Gloria P. and William E. Dean, Jr. Jane and Irwin Deister, Jr. Monte A. and Kristen G. Del Monte Rosemarie DeLand James R. Devine Mary Hunter Dobson J. McGregor and Christine Dodds Magdalen Skuba Edwards Michael and Elizabeth Eichler Meelad Ellis Thomas F. and Susan W. Essman Hal and Donna Estry Murray J. and Lynda L. Feiwell Joe and Beth Fitzsimmons H. Halladay and Jean E. Flynn Victor P. and Mary E. Freliga Dasa and Nalini Gangadhar Tom and Maureen Grace Gardner Richard and Lisa Garfinkel Sunir J. Garg, M.D., and Stella Luo, M.D. Larry and Mary Gerbens James and Charlene Glerum Martin R. and Rise Goode Mr. Waleed K. Gosaynie Joanne R. Gradowski Grand Lodge of Michigan Kathryn G. Gray Daniel and Norma Green Robert and Teresa Grosserode Eugene R. and Phoebe M. Harcum Theodore and Naomi Harrison David S. Hemmings, M.D. Myron Hepner Barry and Mary Ann Hoffman Robert O. and Carolyn S. Hoffman Helen W. Holmes Trust James and Kathy Holmes Walter L. and Barbara J. Hungerford Jewish Community Foundation of Ann Arbor Joja Hospitality, LLC Professor Judy M. Judd Mr. Leslie Kahn and Ms. Irene Watcher Rita Barbour Kern Nancy and Jeffrey Khan, M.D. James G. and Carolyn Knaggs Paul and Jennifer Lee John and Suzanne Ley Kim Lindenmuth and Matthew Bueche William W. Love Frode and Marilyn Maaseidvaag James Albert Maraldo Donald and Jacqueline McCulloch Judge Joe B. McDade and Mrs. Mary W. McDade Carolyn E. Mesara
Dr. and Mrs. P. Anthony Meza Dean and Lynn Mitchell Nicholas and Shannon Mittica Cruse W. Moss Andrew Moyes Ken and Pat Musson John and Phyllis Napley Mark and Susan Orringer Pam W. Parrish Allen and Kathy Pearce Michael Petersen and Elizabeth Binasio Jeffrey A. Pike Scott M. Pinter, M.D. Sally J. Pryce James and Nancy Ravin Rebekah Assembly of Michigan Jonathan and Robin Rowe Ellajane S. Rundles Stephen J. and Kim R. Saxe David W. Schmidt, M.D. Dr. and Mrs. Gregory L. Skuta Francis Soans, M.D. Mark and Romana Solent Peter K. and Faye B. Speert Alan and Gail Sugar Errol R. and Berry Sweet Michele Tameris-Cook Edward and Karen Tenner James B. Thompson and Mary Ann Brandt Victoria Tkach Triford Foundation Adele and Peter Vaculik Andrew Vine and Caroline Blane Richard L. and Kay E. Watnick Lee S. and Stephen T. Webster John and Carol Weigel Drs. Adrienne West and Mark Hemmila Herbert E. Weston George C. and Cindy Whitaker Marina V.N. and Robert F. Whitman Alfred and Carol Wick Mary June Wilkinson The Lawrence and Sylvia Wong Foundation Fuxiang and Fenfen Zhang Kate and Jeffrey Zink
$500 to $999 Roger D. Arnett Lana L. Berry Robert D. Biggs, M.D. Steven A. Boskovich, M.D. James and Jacqueline Bowen Arlene R. Caon Richard and Enid Carlin Hideki and Tomomi Chuman Grant and Alicia Comer Mr. Frank and Dr. Theresa Cooney Innovation in vision
With gratitude for gifts made from July 1, 2011, through June 30, 2012 Arnold and Susan Coran Evonne Damianos Roland and Louise W. DeMartin Roberta Demott-Friberg Gayle D. Dickerson John S. Dunn Deborah Eadie Cheryl and Bruce Elliott The Estate of Emily Joslin Robert and Cassandra Estes Sharon A. Fox Harry C. Gibson, M.D. Mark and Mary Hetrick Millicent Higgins, M.D. Ada Sue Hinshaw Cheryl Huey, M.D. Ida L. Iacobucci Christine G. James James A. Johnson Mark and Linda Johnson Daniel and Rose Kachnowski Dr. Alon and Heidi Kahana Michael A. Kipp, M.D. James and Carolyn Knaggs Joseph Krajcik Sam and Marilyn Krimm Dr. Stuart P. Landay and Ms. Susan L. Bathke Professor Emeritus Myra A. Larson Robert C. Leland, Jr. Richard Alan Lewis and Patricia N. Lewis Hugh Logan Shahzad I. Mian and Uzma Ahmad Dr. Michel and Alice Nasif Betsy and Ken Nisbet Patrick J. Parden, M.D. Alexander E. and Diane L. Pogrebniak Donald and Debra Puro Iva Jean Roe James Michael Rosenfield Dr. Siv B. Saetre Donald and Jane Schriver Yamina Sebihi and Brian P. Rowan Marvin and Marci Shulman Becky and Doug Spaly James P. and Dorothy Symons Susan and David Thoms Tina D. Turner, M.D. David R. Wagner Joseph Brennan Walsh, M.D. Elise Weisback Katherine A. Whitney Dr. and Mrs. Keith M. Williams Jung and Chiung Yao Wu Xi Chapter of Delta Gamma Foundation Dr. Tetsuya Tamamoto Thaddeus and Joanne Zolty
$100 to $499 Anonymous Donors (19) Joshua B. Albertson and Roslyn M. Stahl Ann T. Alexander Lyle and Margaret Allis Dr. Krista Anderson Peter and Patricia Antonacopoulos Assumption Greek Orthodox Church Samuel and Mary Backos Richard and Madalynn Bair Beverly and George Baker Lawrence A. Barnes Lois and David Baru Theodore and Patti Bash Anne and Donald F. Baty, Jr. Harry E. Beeson Stanley and Joy Berent Lois Bereza Dr. and Mrs. Werner G. Bergen Cagri and Sheila Besirli Ralph H. Beuhler Michael and Clarita Bishel Justin Gottlieb and Barbara Blodi Edward L. and Martha Boggs, Jr. Stephen and Danielle Boorstein Frances R. Bosel Daniel L. Braden William and Julie Bromley Margaret Brown Henry J. and Jean L. Brown Wilbur and Carolyn Burkett J. Scott and Nancy Burns Christine R. Buse Norman and Maureen Campbell Helen Cargas J.R. and Elaine J. Carson Claudette J. Casello Sherry Chang Anne M. Chase Christina and Nick Cheolas Robert and Kay Chesebro Benjamin and Deborah Chong Mary and Raymond Christl Marilyn Citron John and Carolyn Clark Martha and James Cleary Shirley CoeBeck and David Beck Ms. Alice S. Cohen Carl and Maria Constant Patrick and Laura Coppens Ellen L. Coulthard Donald R. Cox MargaretAnn Cross and James Van Fleteren Alicia Curley Cathleen A. Curley William and Carol Cutler Larisa and Arthur Czabaniuk Lyubica Dabich, M.D.
university of michigan kellogg eye center
“As a young investigator in the process of developing a research program, I am grateful for early funding and awards from individual donors and privately funded organizations. Such generosity allows me to study retinal diseases and their mechanisms — with the goal of developing new treatments to prevent or reverse associated vision loss.” — Patrice E. Fort, Ph.D., M.S.
With gratitude for gifts made from July 1, 2011, through June 30, 2012
“The Dryer Career Development Professorship has provided the resources needed to build a clinical studies infrastructure that will serve as the foundation for the next generation of clinical research we are building at Kellogg. These studies will enable us to more quickly bring new, more effective treatments to our patients.” — Grant M. Comer, M.D., M.S., Assistant Professor Edward T. and Ellen K. Dryer Career Development Professor
Barbara Dalasinski John and Elizabeth Dallas Dave and Marsha Darrah Dolores D. Daudt James E. Davies Prof. William and Virginia Dawson Cecelia and Homer Deaton Mary Jo and William Demopoulos Dr. M. Kenneth and Arvene Dickstein Richard and Joann Dionne John A. Dodds Marlene and Paul Dodge Mr. and Mrs. Kenneth R. Dornbrook Dow Corning Corporation Blake and Melba Doyle Deborah Drous Joyce P. Duke Mr. and Mrs. Wilbert L. Ehmann Richard L. Ellis Nancie Entenmann Michael J. Fanola Dr. and Mrs. Robert Fazio Bryn A. and Suzanne M. Fick Esther M. Floyd Food Services, Inc. Randee Freedman Ralph N. Funk Jeannine M. Galetti Patricia M. Gardner Thomas and Melissa Gauntlett GE Foundation Michael J. Geiss III, M.D. James and Patricia Giftos Jacqueline and Richard Gilbert Hilary Grabe and Michael Mayer Richard L. Greer Mark W. and Susan S. Griffin Norman Grigsby Terry A. Gromacki and Cassie Lyn Barnhardt Mrs. Adele Gudes
Geza L. and Elizabeth F. Gyorey Steven and Iris Haak Margaret Hagen Mr. Kenneth Haller Michael W. and Molli Hallum Hugh and Janet Harness Timothy C. Harris Larry and Jocelyn Harwood Noriko and Dr. Ken Hashimoto Gerald and Mignon Heppler David and Phyllis Herzig Ruth Heyn, M.D. Jeanne and Conrad Heyner Frederick J. Heyner Tom S. Hill Peter J. Hirth Richard and Jane Hiss Prof. Emer. Gerald P. Hodge Jonell Hollinger Deborah Holloway Mary M. Howrey Margaret M. and James E. Hughes Sungmin Hyung, M.D., Ph.D. Illinois Tool Works Foundation Dr. and Mrs. James D. Izer Richard and Anne Jackson Jim and Valorie Jalsovsky Robert J. Jampel Mr. and Mrs. Kenneth B. Johnson Dr. Mark E. Johnston Norma Johnston Artie Jones and Kimberly Dulimba S. Preston and Dr. Betty B. Jones Mr. and Mrs. Francis J. Joyce Leo Kalyvas, Jr. Charlene and Leo Kay Rosemary S. Kaye Helen D. Kellam Ralph and Priscilla Kinney Phillip and Frances Kish Alexandra Klos
Mary Jo Knight Frank J. Konkel J. David and Grace Kotre Drs. Teresa and Norman Krieger Susan and James Krucki Gerald and Dorothy Kurtz Marie Lane Stephen P. and Candis M. Lang Louis and Gail LaRiche Kurt K. Lark, M.D. Lucille Lefler Mr. and Mrs. F. R. Lehman Gary Lelli and Kelly Bottger Cheryl L. and J. Paul Lemieux Joanne R. Leoni Helios Leung Danute M. Leveckis, M.D., and Timothy Van Every, M.D. Bobbie and Myron Levine Robertson A. Lewis Seymour and Betty Lichter Sherry L. Lindahl Mark and Carol Loessel Thomas Longworth and Carol Cramer A. Letitia Loveless Lonnie and Melissa Loy Sandra Dee Luksch Jane G. Maddox Joseph L. Maggini Carol L. Makielski and Charles D. Lake Richard and Barbara Mannis Linda Manoogian-Fingerle Carl F. Marrs and Julia E. Richards Regent Olivia P. Maynard and S. Olof Karlstrom Roderick A. McDonald Lloyd and Helen Mc Kee Kathy A. McMenemy-Williams Laurie and Fredrick Metzger Elaine J. Mickelson Myrna and Newell Miller Innovation in vision
With gratitude for gifts made from July 1, 2011, through June 30, 2012 Alphonse J. Misko Helen L. Mitchell Ms. Marlene M. Moleski John and Linda Morrison Donald and Ann Munro Alphonsus C. Murphy Mr. and Mrs. Albert Nedoff Christine Nelson and Willis Lillard Lawrence and Rebecca Newman Jonathon P. Niemczak Harry and Leeta Nistel Constance and David Osler Mark E. and Barbara C. Overland Joseph Palm Mary Parisi Nicola and Deborah Parravano Shirley and Ara Paul Carol M. Paull Joseph and Betty Pavka Gordon E. Peckham, Sr. Keith and Janet Lee Perkins James and Nancy Pflasterer Sheryl and Douglas Podlewski Linda M. Podojil Joe and Mary Pousak Rebecca and Eric Priebe Robert Rapp Charles Schmitter and Allyn Ravitz William Redfield Mr. and Mrs. Walter F. Redmond Ann M. Reed William and Charlotte Rees Rita and Robert Reske Ms. Ann M. Rice Richard K. Roberts Barbara and Art Rocco David and Ann Rogers Richard Z. and Edie W. Rosenfeld
Dennis A. and Olivia S. Ross Rennie and Michael Roth Michael C. Roustemis Carol and Dave Rundle Donald R. and Barbara Scavarda Linda and Thomas Schalek Mrs. Helen F. Schaper Perry and Faith Schechtman Michael R. Schleif Norma and Ray Schmick Judith and Willard Schneider Eileen Schott John and Karen Schultz Marc Alan Schwartz Frances C. Scott Garrett R. and Emily K. Scott Woodrow and Loulease Sellers Brahm Shapiro and Lorraine Fig Shapiro David and Elvera Shappirio Rohit Shastry Charles Sherman Max and Roni Shtein Ted and Mary Ann Simon Sandra R. Singer Daniel and Julie Sinnott Grace M. Smith Kenneth S. Smith and Donna Geneseo Irene Solent-Field and Matthew G. Field St. Paul Lutheran School John and Alexandra Starr Virginia and Eric Stein Thomas and Jane Stratford S. Stephen Streeter Dr. Charles Shun Su Margaret A. Sullivan Wesley Szpunar
“Support for education enables us to provide our future ophthalmologists and vision scientists with the tools, technologies, and skills needed to make real contributions in a changing health care and scientific environment.” — Shahzad I. Mian, M.D.
Associate Chair for Education and Residency Program Director
university of michigan kellogg eye center
Duane Tarnacki Frank D. Tennent Tom Thomas Debra Thompson and William Strong Elaine J. Thompson A. Richard Tischler Peter and Barbara Torrice Karen and Arthur Tousignant Dr. and Mrs. Steve S. Tsangalias Roula and Fereniki Tsaprailis Herbert and Anne Upton Lois Van Houten Ronald Vanderlugt Michael and Tina Varlamos George Verras Sue Vitous Lampros (Louis) Vlahantones George and Chrisanthy Volis Susan Wabeke Richard and Edith Wacksman Claudia M. Wagner P. Steven Wainess, D.D.S. Arthur and Renata Wasserman Christian and Ella Weber Carolyn Jean Weigle Dr. and Mrs. William W. Wells Avis L. White Dr. Patrick T. and Mary White Marallyn M. Wight John Williams Jeneane Wise David and Phyllis Wittrock Ford L. Wright Michael and Kathleen Yang Gloria Yff Ernest Zachary Allan C. Zander Thomas and Delle ZurSchmiede
With gratitude for gifts made from July 1, 2011, through June 30, 2012 In Memory Of The Kellogg Eye Center is honored to have received gifts in memory of the following individuals. Margaret Baier Norbert Bereza David Berry Idelle Binder Sylvia Breakstone Edmund M. Brownell Gertrude Callaway Jim Caon Ruth M. Clarke Paul and Kate Coleman Kenneth Cosby Howard Courtney Mildred Dillard George Duke, Jr. Harold F. Falls, M.D. Pearl A. Fitzpatrick Ann Flaherty Murphy J. Scott Fleming F. Bruce Fralick, M.D. Bartley R. Frueh, M.D. Dr. Henry Gray George Harris Jean D. Harrison Kathleen Hatt Dr. Sivana T. Heller C. Theodore Larson, FAIA William Leoni Susan Lichter Lucille Maggini Richard Martin Linn Ann Mason Agnes McMenemy Minnie Menskey Jack Morris Charles Mule JoAnne Nedoff Ernestina Parravano Harry Piper Heinz Prechter Gordon Riehl Peggy Roberts Carl Roe Dr. Walter Z. Rundles, Jr.
Earl Schaper Julianna Simon David M. Smith, M.D. Eric Stein Marguerite W. Sullivan Randall Wallach Dr. Edwin Wight Elizabeth Wilhoff Theodore Woehrle George Zissis
In Honor Of The following individuals were honored through gifts to the Kellogg Eye Center. Steven Bisson Edith Brown Deborah Dayton Jane Griffith Elliott Victor M. Elner, M.D., Ph.D. Frances and David H. Grossman Brendan Heppner Joseph and Lori Hymes Dr. Frank D. Johnson Mark W. Johnson, M.D. David Jude Alon Kahana, M.D., Ph.D. Noah Kotre Paul R. Lichter, M.D. Paul and Carolyn Lichter Connie Mann Roger F. Meyer, M.D. Shahzad I. Mian, M.D. Mark Milazzo Sayoko E. Moroi, M.D., Ph.D. Richard A. Pittsley, M.D. Stephen J. Saxe, M.D. Roni M. Shtein, M.D. Michael W. Smith-Wheelock, M.D. H. Kaz Soong, M.D. Alan Sugar, M.D. Clare Van Fleteren Lillian Weigle Rebecca A. Wu, M.D. David N. Zacks, M.D., Ph.D.
Bequests and Other Planned Gifts It is with deep gratitude that we recognize the following individuals for making the Kellogg Eye Center a part of their estate plans. Frank J. and Helga Arnold Nancy Bender Anne S. Benninghoff Rhoda L. and Roger M. Berkowitz Robert D. Biggs, M.D. Gloria P. and William E. Dean, Jr. Ralph M. Fox Helen A. (Poorbaugh) Freedman Larry and Mary Gerbens Conrad L. Giles Ed and Sue Gorney Ida Lucy Iacobucci Mrs. Harry Krashen Edward and Duffy Ladenberger Harry and Eva McGee M. Joseph and Beverly McKenney Bruce L. and Roberta Oliver Alvin Perkiss Sally J. Pryce Joanne A. Rackham Katherine M. Rackham Mrs. Shirley M. Schaible Alice and Ronald Shankland E.H. Newel and Rosemary Smith Russell A. Stephens and Phyllis A. Capogna James B. Thompson and Mary Ann Brandt David and Jayne VerLee
Only those who gave their permission are included above. The Kellogg Eye Center greatly values our donors, and we make every effort to ensure the accuracy of the honor roll. Please call us at 734.615.0243 if you note any errors.
Innovation in vision
Faculty honors and recognition
Steven F. Abcouwer, Ph.D. Editorial Board, American Journal of Physiology: Endocrinology & Metabolism Editorial Board, Journal of Clinical & Experimental Ophthalmology Study Section, Research Grant Review Committee, American Diabetes Association Research Funding Program
Monte A. Del Monte, M.D. (cont.) Member and Grant Reviewer, Scientific Advisory Committee, Knightâ€™s Templar Eye Research Foundation, Schaumburg, IL Special Invited International Keynote Speaker, 3rd Chinese Pediatric Ophthalmology Society Meeting, Xiamen, China Chair, Program Committee, American Orthoptic Council
David A. Antonetti, Ph.D. Study Section, National Institutes of Health Diseases and Pathophysiology of the Visual System Editorial Board, Tissue Barriers
Hakan Demirci, M.D. Best Doctors in America
Steven M. Archer, M.D. Best Doctors in America U.S. News & World Report Top Doctor Guest of Honor, 736th meeting of the New England Ophthalmological Society, Boston, MA Robb-Peterson Lecture, Childrenâ€™s Hospital Pediatric Ophthalmology Fellowship Alumni Meeting, Boston, MA Eugene R. Folk, M.D., Visiting Professorship, Illinois Eye and Ear Infirmary, Chicago, IL Arthur W. Stickle Lecture, Washington University, St. Louis, MO Lifetime Honor Award, American Association for Pediatric Ophthalmology and Strabismus Cagri G. Besirli, M.D., Ph.D. Heed Fellow, Heed Ophthalmic Foundation Fellow, Society of Heed Fellows Ronald G. Michels Fellowship Award 15th Fellow Research Award, The Retina Society Brenda L. Bohnsack, M.D., Ph.D. Heed Fellow, Heed Ophthalmic Foundation Fellow, Society of Heed Fellows Resident and Fellow Research Forum, Association of University Professors of Ophthalmology Research to Prevent Blindness Career Development Award Theresa M. Cooney, M.D. Board member and delegate to the Michigan State Medical Society for the Michigan Society of Eye Physicians and Surgeons Wayne T. Cornblath, M.D. Best Doctors in America Education Liaison Committee, North American Neuro Ophthalmology Society - American Academy of Ophthalmology Monte A. Del Monte, M.D. Best Doctors in America U.S. News & World Report Top Doctor Top Doctor, Hour Detroit North American Chair, Program Committee, Sub-Specialty Day in Pediatric Ophthalmology, Pan American Association of Ophthalmology, Buenos Aries, Argentina Invited Scientific Advisor and Lead Faculty, WebMDCentral
university of michigan kellogg eye center
Raymond S. Douglas, M.D., Ph.D. Best Doctors in America The Endocrine Society International Award for Excellence in Published Clinical Research Susan G. Elner, M.D. Best Doctors in America Executive Editor, American Journal of Ophthalmology Victor M. Elner, M.D., Ph.D. Best Doctors in America U.S. News & World Report Top Doctor Study Section C Grant Reviewer, National Eye Institute Chair, ASOPRS Awards Committee Jerome I. Finkelstein, M.D., FACS Best Doctors in America Bruce A. Furr, C.O., M.S.P.H. Past President, American Association of Certified Orthoptists Member, Executive Committee, American Association of Certified Orthoptists Co-host, American Academy of Ophthalmology/American Orthoptic Council/American Association of Certified Orthoptists Strabismus Symposium, American Academy of Ophthalmology Annual Meeting Member, International Affairs Committee, American Association for Pediatric Ophthalmology and Strabismus Editorial Board, American Orthoptic Journal Christopher Gappy, M.D. Peer Reviewer, Journal of American Association for Pediatric Ophthalmology and Strabismus Thomas W. Gardner, M.D., M.S. Healthy Eyes Taubman Scholar, A. Alfred Taubman Medical Research Institute, University of Michigan Medical School and JDRF Research to Prevent Blindness Physician-Scientist Award Associate Editor, Diabetes and Acta Ophthalmologica Editorial Board, Journal of Ocular Biology, Diseases, and Informatics Scientific Advisory Board, Diabetic Retinopathy Clinical Research Network Scientific Review Committee, T1D Exchange Biobank
Faculty honors and recognition
Thomas W. Gardner, M.D., M.S. (cont.) External Scientific Advisory Board, European Consortium for the Early Treatment of Diabetic Retinopathy Juvenile Diabetes Foundation International Medical Science Review Committee: Clinical Affairs Advisory Committee Steering Committee, Lasker Foundation/International Retina Research Foundation Initiative on Diabetic Retinopathy Richard E. Hackel, M.A., C.R.A., F.O.P.S. Member, Board of Education, Ophthalmic Photographers’ Society John R. Heckenlively, M.D. Best Doctors in America U.S. News & World Report Top Doctor Associate Editor, EYE Peter F. Hitchcock, Ph.D. Associate Dean for Academic Programs and Initiatives, Rackham Graduate School Chair, Retinal Cell Biology Programming Committee for the Association for Research in Vision and Ophthalmology Academic Editor, PLoS ONE Ida L. Iacobucci, C.O. Lifetime Achievement Award for 54 Years’ Service, American Association of Certified Orthoptists Thiran Jayasundera, M.D., FRCSC, FRANZCO Associate Editor, BMC Ophthalmology Mark W. Johnson, M.D. Best Doctors in America Named one of 135 Leading Ophthalmologists in America by Becker’s ASC Review Elected to membership in the Gass Fluorescein Club Chair, Committee on Programs, American Ophthalmological Society Treasurer and Executive Committee, The Retina Society Member, Nominating Committee, The Retina Society Editorial Board, American Journal of Ophthalmology Editorial Board, Retina Editorial Board, Retinal Physician Alon Kahana, M.D., Ph.D. Best Doctors in America Alliance for Vision Research Award Taubman Emerging Scholar, A. Alfred Taubman Medical Research Institute, University of Michigan Medical School Michael Blumenthal Keynote Lecture, Israel Microsurgical Convention, Eilat, Israel Research to Prevent Blindness Career Development Award
Paul P. Lee, M.D., J.D. Best Doctors in America U.S. News & World Report Top Doctor Editorial Board, Archives of Ophthalmology Board of Directors, American Board of Ophthalmology Board of Directors, ARVO Foundation Board of Advisors, Hoskins Center for Patient Safety and Quality, American Academy of Ophthalmology G. Victor Simpson, M.D., Lecture, Washington Hospital Center (Georgetown University), Washington, D.C. Ernest K. Goodner Lecture, University of California at San Francisco Knapp Symposium, American Ophthalmological Society Academia Ophthalmologica Internationalis Paul R. Lichter, M.D., FACS Best Doctors in America U.S. News & World Report Top Doctor President, Academia Ophthalmologica Internationalis Board of Trustees, International Council of Ophthalmology Chair, Clinical and Educational Conflict of Interest Committee, University of Michigan Medical School Shahzad I. Mian, M.D. Best Doctors in America Patrick Regan O’Connor, M.D., Memorial Lecture, University of Louisville Ralph and Sophie Heintz Lecture, 38th Annual H. Bruce Ostler Association of Proctor Fellows Meeting Editorial Board, Cornea Cornea Editor for the Ophthalmic News and Education Network Board of Directors, Cornea Society Policy and Position Review Committee, Eye Bank Association of America Accreditation Board, Eye Bank Association of America Program Director’s Council, Association of University Professors in Ophthalmology Deputy Section Leader, Council, American Academy of Ophthalmology Cornea Representative, Ophthalmology Leadership Advocacy Group Sayoko E. Moroi, M.D., Ph.D. Best Doctors in America ARVO Foundation for Eye Research, Certificate of Appreciation for Service as a Developing Country Eye Researcher Travel Fellowship Mentor Planning Committee and Glaucoma Subcommittee, National Eye Health Education Program, National Eye Institute, National Institutes of Health Ad Hoc Member, Study Section, Diseases and Pathophysiology of the Visual System, National Eye Institute
Innovation in vision
Faculty honors and recognition
David C. Musch, Ph.D., M.P.H. Editorial Board, Ophthalmology Editorial Board, Retina Preferred Practice Patterns Committee, American Academy of Ophthalmology Advisory Board, Cochrane Eyes and Vision Group Data and Safety Monitoring Board Appointments: • Corneal Preservation Time Study, NEI, NIH (chair) • Hydrus IV Phase 3 study, Ivantis, Inc., Irvine, CA (chair) • Sirolimus Treatment of Geographic AMD Phase 2 study, NEI, NIH (member) • Leber Congenital Amaurosis Treatment Phase 3 study, Children’s Hospital of Philadelphia (member) Christine C. Nelson, M.D., FACS Best Doctors in America Top Doctor, Hour Detroit Advisory Board, Women in Ophthalmology Donald G. Puro, M.D., Ph.D. Best Doctors in America Julia E. Richards, Ph.D. Fellow, Association for Research in Vision and Ophthalmology League of Research Excellence, University of Michigan Medical School Textbook award: “Outstanding Academic Title” award from the journal Choice: Current Reviews for Academic Libraries for “The Human Genome: A User’s Guide” third edition, by Julia E. Richards and R. Scott Hawley Roni M. Shtein, M.D., M.S. Young Physician Leader, Eye Bank Association of America Outstanding Research Mentor Award, University of Michigan Undergraduate Research Opportunities Program Achievement Award, American Academy of Ophthalmology Terry J. Smith, M.D. Best Doctors in America The Endocrine Society International Award for Excellence in Published Clinical Research League of Research Excellence, University of Michigan Medical School Research to Prevent Blindness Physician-Scientist Award Board of Directors, National Graves’ Disease Foundation Chief Medical and Scientific Officer, National Graves’ Disease Foundation Board of Scientific Advisors, Guthy-Jackson Foundation Michael W. Smith-Wheelock, M.D. Best Doctors in America
university of michigan kellogg eye center
H. Kaz Soong, M.D. Best Doctors in America Assistant Editor, Cornea Joshua D. Stein, M.D., M.S. Secretariat Award, American Academy of Ophthalmology Research to Prevent Blindness Physician-Scientist Award Fellow, Center for Health Care Research and Transformation Editor in Chief, Evidence-Based Ophthalmology Alan Sugar, M.D. Best Doctors in America Co-Chair, Institutional Review Boards of the University of Michigan Medical School Editor in Chief, Cornea Secretariat Award, Clinical Education, American Academy of Ophthalmology R. Townley Paton Award Lectureship, Eye Bank Association of America Roger F. Meyer Cornea Lectureship Debra A. Thompson, Ph.D. Executive Editor, Experimental Eye Research Fellow, Association for Research in Vision and Ophthalmology Susan S. Thoms, M.D. Best Doctors in America Jonathan D. Trobe, M.D. Best Doctors in America U.S. News & World Report Top Doctor Section Editor, Ophthalmology, UpToDate Associate Editor (Neuro-Ophthalmology), Medlink Advisory Board, Korean Journal of Ophthalmology Maria A. Woodward, M.D. Basic and Clinical Science Course Committee, American Academy of Ophthalmology Jennifer S. Weizer, M.D. Best Doctors in America Dongli Yang, M.D., Ph.D. Reviewer, Molecular Vision Reviewer, BMC Ophthalmology David N. Zacks, M.D., Ph.D. Best Doctors in America Terry J. Bergstrom Teaching Award * Only peer-selected “Best Doctors” and “Top Doctors” rankings are noted
Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227-39. Antonopoulos C, Stem M, Comer GM. Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab. Clin Ophthalmol. 2011;5:165962. Apkarian AO, Garton HJ, Wesolowski J, Trobe JD. Relapsing dorsal midbrain syndrome following interventions for hydrocephalus in aqueductal stenosis. J Neuroophthalmol. 2012;32(2):124-7. Archer SM. Are amblyopia treatments really all equal? Is that even the right question? Am Orthopt J. 2012;62:1-3. Archer SM. Arguing with success: pulley surgery versus conventional surgery for convergence excess esotropia. J AAPOS. 2012;16(2):110-1. Bajenova NV, Vanderbeek BL, Johnson MW. Change in choroidal thickness after chemotherapy in leukemic choroidopathy. Retina. 2012;32(1):203-5. Besirli CG, Johnson MW. Tractioninduced foveal damage predisposes eyes with pre-existing posterior vitreous detachment to idiopathic macular hole formation. Eye. 2012;26(6):792-5. Besirli CG, Sudhakar P, Wesolowski J, Trobe JD. Serous retinal detachment in hypertensive posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2011;32(11):E203-5. Bian ZM, Elner SG, Khanna H, MurgaZamalloa CA, Patil S, Elner VM. Expression and functional roles of caspase-5 in inflammatory responses of human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2011;52(12):8646-56.
Bohnsack BL, Bhatt R, Kahana A. Nonophthalmic symptoms secondary to ocular torticollis from severe blepharoptosis: an underappreciated but treatable condition. Ophthal Plast Reconstr Surg. 2012;28(2):e36-9. Bohnsack BL, Gallina D, Kahana A. Phenothiourea sensitizes zebrafish cranial neural crest and extraocular muscle development to changes in retinoic acid and IGF signaling. PLoS One. 2011;6(8):e22991. Bohnsack BL, Gallina D, Thompson H, Kasprick DS, Lucarelli MJ, Dootz G, Nelson CC, McGonnell IM, Kahana A. Development of extraocular muscles requires early signals from periocular neural crest and the developing eye. Arch Ophthalmol. 2011;129(8):1030-41. Bohnsack BL, Kasprick DS, Kish PE, Goldman D, Kahana A. A zebrafish model of Axenfeld-Rieger syndrome reveals that pitx2 regulation by retinoic acid is essential for ocular and craniofacial development. Invest Ophthalmol Vis Sci. 2012;53(1):7-22. Briceno C, Douglas RS. Orbital and periorbital infections. Arch Ophthalmol. 2012;130(2):233-4. Chaki M, Hoefele J, Allen SJ, Ramaswami G, Janssen S, Bergmann C, Heckenlively JR, Otto EA, Hildebrandt F. Genotypephenotype correlation in 440 patients with NPHP-related ciliopathies. Kidney Int. 2011;80(11):1239-45. Chen C, Thompson DA, Koutalos Y. Reduction of all-trans retinal in vertebrate rod photoreceptors requires the combined action of RDH8 and RDH12. J Biol Chem. 2012 13;287(29):24662-70. Epub 2012 May 23.
Cheng H, Khan NW, Roger JE, Swaroop A. Excess cones in the retinal degeneration rd7 mouse, caused by the loss of function of orphan nuclear receptor Nr2e3, originate from early-born photoreceptor precursors. Hum Mol Genet. 2011;20(21):410215. Cho RI, Elner VM, Nelson CC, Frueh BR. The effect of orbital decompression surgery on lid retraction in thyroid eye disease. Ophthal Plast Reconstr Surg. 201;27(6):436-8. Clark A, Zhu A, Sun K, Petty HR. Cerium oxide and platinum nanoparticles protect cells from oxidant-mediated apoptosis. J Nanopart Res. 2011;13(10):5547-55. Comer GM, Stem MS, Saxe SJ. Successful salvage therapy of Fusarium endophthalmitis secondary to keratitis: an interventional case series. Clin Ophthalmol. 2012;6:721-6. Cooney TM, Wu A, Wilkes G, Finkelstein JI, Musch DC. The effects of systemic alpha1-adrenoreceptor antagonists on pupil diameter. Br J Ophthalmol. 2012;96(4):490-3. Cornblath WT. Neuro-ophthalmology: five new things. Neurol Clin Pract. 2012;2:129-33. Day S, Acquah K, Lee PP, Mruthyunjaya P, Sloan FA. Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol. 201;152(6):1014-20. Epub 2011 Aug 16. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152(2):266-72. Epub 2011 Jun 12.
Innovation in vision
de Paula FH, Khairallah CG, Niziol LM, Musch DC, Shtein RM. Diffuse lamellar keratitis after laser in situ keratomileusis with femtosecond laser flap creation. J Cataract Refract Surg. 2012;38(6):1014-9. Dolman PJ, Cahill K, Czyz CN, Douglas RS, Elner VM, Feldon S, Kazim M, Lucarelli M, Sivak-Collcott J, Stacey AW, Strianese D, Uddin J. Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study. Ophthalmology. 2012;119(2):382-9. Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol. 2011;22(5):385-90. Fausett BV, Trobe JD. Paralysis of accommodation with preserved pupillary function as the initial manifestation of GuillainBarre syndrome. J Neuroophthalmol. 2012;32(2):148-9. Fernando R, Atkins S, Raychaudhuri N, Lu Y, Li B, Douglas RS, Smith TJ. Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc Natl Acad Sci U S A. 2012;109(19):7427-32. Field MG, Yang D, Bian ZM, Petty HR, Elner VM. Retinal flavoprotein fluorescence correlates with mitochondrial stress, apoptosis, and chemokine expression. Exp Eye Res. 2011;93(4):548-55. Fort PE, Losiewicz MK, Reiter CE, Singh RS, Nakamura M, Abcouwer SF, Barber AJ, Gardner TW. Differential roles of hyperglycemia and hypoinsulinemia in diabetes induced retinal cell death: evidence for retinal insulin resistance. PLoS One. 2011;6(10):e26498. Frey T, Antonetti DA. Alterations to the blood-retinal barrier in diabetes: cytokines and reactive oxygen species. Antioxid Redox Signal. 2011;15(5):1271-84.
Fukumoto M, Nakaizumi A, Zhang T, Lentz SI, Shibata M, Puro DG. Vulnerability of the retinal microvasculature to oxidative stress: ion channel-dependent mechanisms. Am J Physiol Cell Physiol. 2012;302(9):C1413-20. Gillespie EF, Papageorgiou KI, Fernando R, Raychaudhuri N, Cockerham KP, Charara LK, Goncalves AC, Zhao SX, Ginter A, Lu Y, Smith TJ, Douglas RS. Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab. 2012;97(5):E740-6. Grabe HM, Bapuraj JR, Wesolowski JR, Parmar H, Trobe JD. Homonymous hemianopia from infarction of the optic tract and lateral geniculate nucleus in deep cerebral venous thrombosis. J Neuroophthalmol. 2012;32(1):38-41. Heckenlively JR. New concept: treating nonproliferative diabetic retinopathy with light adaptation of rods during sleep. Eye. 2011;25(12):1533-4. Hegedus L, Bonnema SJ, Smith TJ, Brix TH. Treating the thyroid in the presence of Gravesâ€™ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):31324. Heise EA, Fort PE. Impact of diabetes on alpha-crystallins and other heat shock proteins in the eye. J Ocul Biol Dis Inform. 2011;4(1-2):62-9. Heitor de Paula F, Kamyar R, Shtein RM, Sugar A, Mian SI. Endothelial keratoplasty without Descemet stripping after failed penetrating keratoplasty. Cornea. 2012;31(6):645-8. Hoa N, Tsui S, Afifiyan NF, Sinha Hikim A, Li B, Douglas RS, Smith TJ. Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Gravesâ€™ disease: apparent role of ADAM17. PLoS One. 2012;7(4):e34173.
university of michigan kellogg eye center
Huang T, Cui J, Li L, Hitchcock PF, Li Y. The role of microglia in the neurogenesis of zebrafish retina. Biochem Biophys Res Commun. 2012;421(2):214-20. Hwang CJ, Khadavi NM, Papageorgiou K, Said J, Chong K, Lee D, Smith TJ, Goldberg RA, Douglas RS. Histopathology of brow fat in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg. 2012;28(1):27-9. Jackson GR, Scott IU, Quillen DA, Walter LE, Gardner TW. Inner retinal visual dysfunction is a sensitive marker of nonproliferative diabetic retinopathy. Br J Ophthalmol. 2012;96(5):699-703. Jarsky T, Cembrowski M, Logan SM, Kath WL, Riecke H, Demb JB, Singer JH. A synaptic mechanism for retinal adaptation to luminance and contrast. J Neurosci. 2011;31(30):11003-11015. Kahana A, Bohnsack BL, Cho RI, Maher CO. Subtotal excision with adjunctive sclerosing therapy for the treatment of severe symptomatic orbital lymphangiomas. Arch Ophthalmol. 2011;129(8):1073-6. Kaiser JM, Imai H, Haakenson JK, Brucklacher RM, Fox TE, Shanmugavelandy SS, Unrath KA, Pedersen MM, Dai P, Willard MF, Bronson SK, Gardner TW, Kester M. Nanoliposomal minocycline for ocular drug delivery. Nanomedicine. 2012 Mar 28. [Epub ahead of print] Kamyar R, Weizer JS, de Paula FH, Stein JD, Moroi SE, John DA, Musch DC, Mian SI. Glaucoma associated with Boston type I keratoprosthesis. Cornea. 2012;31(2):134-9. Kang JH, Loomis S, Wiggs JL, Stein JD, Pasquale LR. Demographic and geographic features of exfoliation glaucoma in 2 United States-based prospective cohorts. Ophthalmology. 2012;119(1):27-35.
Kasprick DS, Kish PE, Junttila TL, Ward LA, Bohnsack BL, Kahana A. Microanatomy of adult zebrafish extraocular muscles. PLoS One. 2011;6(11):e27095. Kim W, Argento A, Rozsa FW, Mallett K. Constitutive behavior of ocular tissues over a range of strain rate. J Biomech Eng. 2012;134(6):061002. Kokkinopoulos I, Colman A, Hogg C, Heckenlively JR, Jeffery G. Age-related retinal inflammation is reduced by 670 nm light via increased mitochondrial membrane potential. Neurobiol Aging. 2012 May 15. [Epub ahead of print] Koreen L, Yoshida N, Escariao P, Niziol LM, Koreen IV, Musch DC, Chang S. Incidence of, risk factors for, and combined mechanism of late-onset openangle glaucoma after vitrectomy. Retina. 2012;32(1):160-7. Kowalski JW, Rentz AM, Walt JG, Lloyd A, Lee J, Young TA, Chen WH, Bressler NM, Lee PP, Brazier JE, Hays RD, Revicki DA. Rasch analysis in the development of a simplified version of the National Eye Institute visual-function questionnaire-25 for utility estimation. Qual Life Res. 2012;21(2):323-34. Epub 2011 Aug 4. Kramer BC, Musch DC, Niziol LM, Weizer JS. Reliability of simultaneous visual field testing. Ophthalmology. 2012;119(2):304-7. Kymes SM, Lambert DL, Lee PP, Musch DC, Siegfried CJ, Kotak SV, Stwalley DL, Fain J, Johnson C, Gordon MO. The development of a decision analytic model of changes in mean deviation in people with glaucoma: the COA model. Ophthalmology. 2012;119(7):1367-74. Epub 2012 Apr 25.
Lambert SR, Archer SM, Wilson ME, Trivedi RH, Del Monte MA, Lynn M. Longterm outcomes of undercorrection versus full correction after unilateral intraocular implantation in children. Am J Ophthalmol. 2012;153(4):602-8. Lass JH, Beck RW, Benetz BA, Dontchev M, Gal RL, Holland EJ, Kollman C, Mannis MJ, Price F, Jr., Raber I, Stark W, Stulting RD, Sugar A. Baseline factors related to endothelial cell loss following penetrating keratoplasty. Arch Ophthalmol. 2011;129(9):1149-54. Lee BJ, Elner SG, Douglas RS, Elner VM. Island pedicle and horizontal advancement cheek flaps for medial canthal reconstruction. Ophthal Plast Reconstr Surg. 2011;27(5):376-9. Lee BJ, Gupta S, Flint A, Singer TR, Elner VM. Pigmented orbital mass due to remote pencil trauma. Ophthal Plast Reconstr Surg. 2012;28(3):e67-8. Lee BJ, Nelson CC, Lewis CD, Perry JD. External dacryocystorhinostomy outcomes in sarcoidosis patients. Ophthal Plast Reconstr Surg. 2012;28(1):47-9. Lee BJ, Nelson CC. Intralesional interferon for extensive squamous papilloma of the eyelid margin. Ophthal Plast Reconstr Surg. 2012;28(2):e47-8. Lee PP, Dzau J. Emergency department use for eye care services and future directions in care. Arch Ophthalmol. 2012;130(1):106-7. Lee S, Douglas RS. Systemic MALToma with presumed choroidal involvement. Arch Ophthalmol. 2012;130(3):379.
Liu Y, Gibson J, Wheeler J, Kwee LC, Santiago-Turla CM, Akafo SK, Lichter PR, Gaasterland DE, Moroi SE, Challa P, Herndon LW, Girkin CA, Budenz DL, Richards JE, Allingham RR, Hauser MA. GALC deletions increase the risk of primary open-angle glaucoma: the role of Mendelian variants in complex disease. PLoS One. 2011;6(11):e27134. Loftus JV, Sultan MB, Pleil AM; Macugen 1013 Study Group. Changes in visionand health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. Invest Ophthalmol Vis Sci. 2011;52(10):7498-505. [Lee P â€“ Collaborator] Losiewicz MK, Fort PE. Diabetes impairs the neuroprotective properties of retinal alpha-crystallins. Invest Ophthalmol Vis Sci. 2011;52(9):5034-42. Louttit MD, Kopplin LJ, Igo RP, Jr., Fondran JR, Tagliaferri A, Bardenstein D, Aldave AJ, Croasdale CR, Price MO, Rosenwasser GO, Lass JH, Iyengar SK; FECD Genetics Multi-Center Study Group. A multicenter study to map genes for Fuchs endothelial corneal dystrophy: baseline characteristics and heritability. Cornea. 2012;31(1):26-35. [Sugar A, Mian S, Soong HK â€“ Collaborators] Luttrull JK, Sramek C, Palanker D, Spink CJ, Musch DC. Long-term safety, highresolution imaging, and tissue temperature modeling of subvisible diode micropulse photocoagulation for retinovascular macular edema. Retina. 2012;32(2):375-86. Morse AR, Lee PP. Comparative effectiveness: insights on treatment options for open-angle glaucoma. Arch Ophthalmol. 2012;130(4):506-7.
Innovation in vision
Muir KW, Ventura A, Stinnett SS, Enfiedjian A, Allingham RR, Lee PP. The influence of health literacy level on an educational intervention to improve glaucoma medication adherence. Patient Educ Couns. 2012;87(2):160-4. Murakami T, Frey T, Lin C, Antonetti DA. Protein kinase Cbeta phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factorinduced permeability in vivo. Diabetes. 2012;61(6):1573-83. Musch DC, Gillespie BW, Niziol LM, Lichter PR, Varma R. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2011;118(9):1766-73. Musch DC, Niziol LM, Stein JD, Kamyar RM, Sugar A. Prevalence of corneal dystrophies in the United States: estimates from claims data. Invest Ophthalmol Vis Sci. 2011;52(9):6959-63. Nakaizumi A, Puro DG. Vulnerability of the retinal microvasculature to hypoxia: role of polyamine-regulated K(ATP) channels. Invest Ophthalmol Vis Sci. 2011;52(13):9345-52. Nakaizumi A, Zhang T, Puro DG. The electrotonic architecture of the retinal microvasculature: diabetes-induced alteration. Neurochem Int. 2012 Feb 13. [Epub ahead of print] Nallasamy S, Anninger WV, Quinn GE, Kroener B, Zetola NM, Nkomazana O. Survey of childhood blindness and visual impairment in Botswana. Br J Ophthalmol. 2011;95(10):1365-70.
Neveling K, Collin RW, Gilissen C, van Huet RA, Visser L, Kwint MP, Gijsen SJ, Zonneveld MN, Wieskamp N, de Ligt J, Siemiatkowska AM, Hoefsloot LH, Buckley MF, Kellner U, Branham KE, den Hollander AI, Hoischen A, Hoyng C, Klevering BJ, van den Born LI, Veltman JA, Cremers FP, Scheffer H. Next-generation genetic testing for retinitis pigmentosa. Hum Mutat. 2012;33(6):963-72. Newman-Casey PA, Talwar N, Nan B, Musch DC, Stein JD. The relationship between components of metabolic syndrome and open-angle glaucoma. Ophthalmology. 2011;118(7):1318-26. Papageorgiou KI, Hwang CJ, Chang SH, Jarullazada I, Chokron Garneau H, Ang MJ, King AJ, Mancini R, Douglas RS, Goldberg RA. Thyroid-associated periorbitopathy: eyebrow fat and soft tissue expansion in patients with thyroidassociated orbitopathy. Arch Ophthalmol. 2012;130(3):319-28. Papageorgiou KI, Mancini R, Garneau HC, Chang SH, Jarullazada I, King A, Forster-Perlini E, Hwang C, Douglas RS, Goldberg RA. A three-dimensional construct of the aging eyebrow: the illusion of volume loss. Aesthet Surg J. 2012;32(1):46-57. Patel SS, Lee BJ, Elner VM. Painful traumatic neuroma after orbital decompression surgery. Arch Ophthalmol. 2012;130(4):530-1. Pattnaik BR, Hughes BA. Effects of KCNQ channel modulators on the M-type potassium current in primate retinal pigment epithelium. Am J Physiol Cell Physiol. 2012;302(5):C821-33. Plageman TF, Jr., Zacharias AL, Gage PJ, Lang RA. Shroom3 and a Pitx2-Ncadherin pathway function cooperatively to generate asymmetric cell shape changes during gut morphogenesis. Dev Biol. 2011;357(1):227-34.
university of michigan kellogg eye center
Puro DG. Retinovascular physiology and pathophysiology: new experimental approach/new insights. Prog Retin Eye Res. 2012;31(3):258-70. Runkle EA, Antonetti DA. The blood-retinal barrier: structure and functional significance. Methods Mol Biol. 2011;686:13348. Runkle EA, Sundstrom JM, Runkle KB, Liu X, Antonetti DA. Occludin localizes to centrosomes and modifies mitotic entry. J Biol Chem. 2011;286(35):30847-58. Schneider EW, Geraets RL, Johnson MW. Pars plana vitrectomy without adjuvant procedures for repair of primary rhegmatogenous retinal detachment. Retina. 2012;32(2):213-9. Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol. 2011;5:1151-65. Shtein RM, Elner SG, Bian ZM, Elner VM. IL-8 and MCP gene expression and production by LPS-stimulated human corneal stromal cells. Int J Inflam. 2012;2012:714704. Shtein RM, Kelley KH, Musch DC, Sugar A, Mian SI. In vivo confocal microscopic evaluation of corneal wound healing after femtosecond laser-assisted keratoplasty. Ophthalmic Surg Lasers Imaging. 2012;43(3):205-13. Shtein RM, Raoof-Daneshvar D, Lin HC, Sugar A, Mian SI, Nan B, Stein JD. Keratoplasty for corneal endothelial disease, 2001-2009. Ophthalmology. 2012;119(7):1303-10. Epub 2012 Apr 17. Shtein RM. Post-LASIK dry eye. Expert Rev Ophthalmol. 2011;6(5):575-82.
Sloan FA, Acquah KF, Lee PP, Sangvai DG. Despite ‘welcome to Medicare’ benefit, one in eight enrollees delay first use of part B services for at least two years. Health Aff. 2012;31(6):1260-8. Smith TJ, Douglas RS. Pharmacotherapy: does selenium supplementation improve Graves’ ophthalmopathy? Nat Rev Endocrinol. 2011;7(9):505-6. Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):291-302. Smith TJ, Padovani-Claudio DA, Lu Y, Raychaudhuri N, Fernando R, Atkins S, Gillespie EF, Gianoukakis AG, Miller BS, Gauger PG, Doherty GM, Douglas RS. Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves’ disease. J Clin Endocrinol Metab. 2011;96(12):3827-37. Sofat R, Casas JP, Webster AR, Branham KE, Hingorani AD. Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int J Epidemiol. 2012;41(1):250-62. Stanton CM, Yates JR, den Hollander AI, Seddon JM, Swaroop A, Stambolian D, Fauser S, Hoyng C, Yu Y, Atsuhiro K, Branham KE, Othman M, Chen W, Kortvely E, Chalmers K, Hayward C, Moore AT, Dhillon B, Ueffing M, Wright AF. Complement factor D in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52(12):8828-34. Stein JD, Grossman DS, Mundy KM, Sugar A, Sloan FA. Severe adverse events after cataract surgery among Medicare beneficiaries. Ophthalmology. 2011;118(9):1716-23.
Stein JD, Kim DD, Peck WW, Giannetti SM, Hutton DW. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol. 2012;130(4):497-505. Stein JD, Kim DS, Mundy KM, Talwar N, Nan B, Chervin RD, Musch DC. The association between glaucomatous and other causes of optic neuropathy and sleep apnea. Am J Ophthalmol. 2011;152(6):98998. Stein JD, Newman-Casey PA, Talwar N, Nan B, Richards JE, Musch DC. The relationship between statin use and openangle glaucoma. Ophthalmology. 2012 Oct;119(10):2074-81. Epub 2012 Jun 21.
Sudhakar P, Shah GV, Saponara F, Fullen DR, Trobe JD. Central retinal artery occlusion secondary to orbital inflammation in lupus erythematosus profundus. J Neuroophthalmol. 2012;32(1):93-4. Sugar A, Montoya MM, Beck R, Cowden JW, Dontchev M, Gal RL, Kollman C, Malling J, Mannis MJ, Tennant B. Impact of the cornea donor study on acceptance of corneas from older donors. Cornea. 2012 Jan 18. [Epub ahead of print] Tash BR, Bewley MC, Russo M, Keil JM, Sundstrom JM, Antonetti DA, Tian F, Flanagan JM. The occludin and ZO-1 complex, defined by small angle X-ray scattering and NMR, has implications for modulating tight junction permeability. Proc Natl Acad Sci USA. 2012 Jul 3;109(27):10855-60. Epub 2012 Jun 18.
Stein JD, Pasquale LR, Talwar N, Kim DS, Reed DM, Nan B, Kang JH, Wiggs JL, Richards JE. Geographic and climatic factors associated with exfoliation syndrome. Arch Ophthalmol. 2011;129(8):1053-60.
Taylor S, Chen J, Luo J, Hitchcock PF. Light-induced photoreceptor degeneration in the retina of the zebrafish. Methods Mol Biol 2012;884:247-54.
Stein JD, Talwar N, Laverne AM, Nan B, Lichter PR. Trends in use of ancillary glaucoma tests for patients with open-angle glaucoma from 2001 to 2009. Ophthalmology. 2012;119(4):748-58.
Thomas JL, Ochocinska MJ, Hitchcock PF, Thummel R. Using the Tg(nrd:egfp)/ albino zebrafish line to characterize in vivo expression of neurod. PLoS One. 2012;7(1):e29128.
Stein JD, Vanderbeek BL, Talwar N, Nan B, Musch DC, Zacks DN. Rates of nonexudative and exudative age-related macular degeneration among Asian American ethnic groups. Invest Ophthalmol Vis Sci. 2011;52(9):6842-8.
Thompson DA, Khan NW, Othman MI, Chang B, Jia L, Heckenlively JR, Swaroop A. Rd9 is a naturally occurring mouse model of a common form of retinitis pigmentosa caused by mutations in RPGRORF15. PLoS ONE. 2012;7(5):e35865.
Stein JD. Serious adverse events after cataract surgery. Curr Opin Ophthalmol. 2012;23(3):219-25.
Todorich B, Scott IU, Flynn HW, Jr., Johnson MW. Evolving strategies in the management of submacular hemorrhage associated with choroidal neovascularization in the anti-vascular endothelial growth factor era. Retina. 2011;31(9):1749-52.
Sudhakar P, Rodriguez FR, Trobe JD. MRI restricted diffusion in lymphomatous optic neuropathy. J Neuroophthalmol. 2011;31(4):306-9.
Innovation in vision
Tranos PG, Moore A, Pavesio C, Acharya NR, Johnson MW. Diagnostic and therapeutic challenges. Retina. 2012;32(1):191-6. Tsui S, Fernando R, Chen B, Smith TJ. Divergent Sp1 protein levels may underlie differential expression of UDP-glucose dehydrogenase by fibroblasts: role in susceptibility to orbital Gravesâ€™ disease. J Biol Chem. 2011;286(27):24487-99. Ulmer M, Li J, Yaspan BL, Ozel AB, Richards JE, Moroi SE, Hawthorne F, Budenz DL, Friedman DS, Gaasterland D, Haines J, Kang JH, Lee R, Lichter PR, Liu Y, Pasquale LR, Pericak-Vance M, Realini A, Schuman JS, Singh K, Vollrath D, Weinreb R, Wollstein G, Zack DJ, Zhang K, Young T, Allingham RR, Wiggs JL, Ashley-Koch A, Hauser MA. Genome-wide analysis of central corneal thickness in primary openangle glaucoma cases in the NEIGHBOR and GLAUGEN consortia. Invest Ophthalmol Vis Sci. 2012;3;53(8):4468-74. Epub 2012 Jun 1. Van Herle K, Behne JM, Van Herle A, Blaschke TF, Smith TJ, Yeaman MR. Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases. Annu Rev Pharmacol Toxicol. 2012;52:523-47. Van Hook MJ, Wong KY, Berson DM. Dopaminergic modulation of ganglioncell photoreceptors in rat. Eur J Neurosci. 2012;35(3-4):507-18. VanderBeek BL, Johnson MW. The diversity of traction mechanisms in myopic traction maculopathy. Am J Ophthalmol. 2012;153(1):93-102.
Warden KF, Alizai AM, Trobe JD, Hoff JT. Short-term continuous intraparenchymal intracranial pressure monitoring in presumed idiopathic intracranial hypertension. J Neuroophthalmol. 2011;31(3):202-5. Weick M, Demb JB. Delayed-rectifier K channels contribute to contrast adaptation in mammalian retinal ganglion cells. Neuron. 2011;71(1):166-79. Weizer JS, Musch DC, Niziol LM, Khan NW. Multifocal visual evoked potentials for early glaucoma detection. Ophthalmic Surg Las Imaging 2012;43:335-40. Wiggs JL, Yaspan BL, Hauser MA, Kang JH, Allingham RR, Olson LM, Abdrabou W, Fan BJ, Wang DY, Brodeur W, Budenz DL, Caprioli J, Crenshaw A, Crooks K, Delbono E, Doheny KF, Friedman DS, Gaasterland D, Gaasterland T, Laurie C, Lee RK, Lichter PR, Loomis S, Liu Y, Medeiros FA, McCarty C, Mirel D, Moroi SE, Musch DC, Realini A, Rozsa FW, Schuman JS, Scott K, Singh K, Stein JD, Trager EH, Vanveldhuisen P, Vollrath D, Wollstein G, Yoneyama S, Zhang K, Weinreb RN, Ernst J, Kellis M, Masuda T, Zack D, Richards JE, Pericak-Vance M, Pasquale LR, Haines JL. Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. PLoS Genet. 2012;8(4):e1002654. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, Woodward MA, Miller RA. Rapamycin slows aging in mice. Aging Cell. 2012;11(4):675-82. Epub 2012 Jun 4.
Vanderbeek BL, Zacks DN, Talwar N, Nan B, Musch DC, Stein JD. Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network. Am J Ophthalmol. 2011;152(2):273-82.
university of michigan kellogg eye center
Wissinger B, Schaich S, Baumann B, Bonin M, Jagle H, Friedburg C, Varsanyi B, Hoyng CB, Dollfus H, Heckenlively JR, Rosenberg T, Rudolph G, Kellner U, Salati R, Plomp A, De Baere E, Andrassi-Darida M, Sauer A, Wolf C, Zobor D, Bernd A, Leroy BP, Enyedi P, Cremers FP, Lorenz B, Zrenner E, Kohl S. Large deletions of the KCNV2 gene are common in patients with cone dystrophy with supernormal rod response. Hum Mutat. 2011;32(12):1398406. Woodward MA, Titus M, Mavin K, Shtein RM. Corneal donor tissue preparation for endothelial keratoplasty. J Vis Exp. 2012;64:e3847. Yang D, Elner SG, Chen X, Field MG, Petty HR, Elner VM. MCP-1-activated monocytes induce apoptosis in human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2011;52(8):6026-34. Yao J, Jia L, Khan NW, Zheng QD, Moncrief A, Hauswirth WW, Thompson DA, Zacks DN. Caspase inhibition with XIAP as an adjunct to AAV vector genereplacement therapy: improving efficacy and prolonging the treatment window. PLoS One. 2012;7(5):e37197. Zaidi AA, Brucker AJ, Johnson MW. Diagnostic and therapeutic challenges. Retina. 2011;31(10):2125-8. Zhang L, Sun Y, Johnson MW, Richards JE, Moroi SE. Combined cilioretinal artery and central vein occlusions in juvenile glaucoma. Arch Ophthalmol. 2011;129(9):1231-4. Zhang X, Yang D, Hughes BA. KCNQ5/ K(v)7.5 potassium channel expression and subcellular localization in primate retinal pigment epithelium and neural retina. Am J Physiol Cell Physiol. 2011;301(5):C101726.
Zhao SX, Tsui S, Cheung A, Douglas RS, Smith TJ, Banga JP. Orbital fibrosis in a mouse model of Graves’ disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol. 2011;210(3):369-77. Zhu A, Romero R, Petty HR. An enzymatic colorimetric assay for glucose-6-phosphate. Anal Biochem. 2011;419(2):266-70. Zhu A, Sun K, Petty HR. Titanium doping reduces superoxide dismutase activity, but not oxidase activity, of catalytic CeO(2) nanoparticles. Inorg Chem Commun. 2012;15:235-237. Books / Book Chapters Cho, R.I., Kahana, A. Orbital Exenteration. In: Black EH, Nesi FA, Gladstone GJ, Levine MR, Calvano CJ, eds, Smith and Nesi’s Ophthalmic Plastic & Reconstructive Surgery, 3rd Edition. New York:Springer, 2012, pp 1033-44. De la Parra P, Sugar A, Mian SI. Conjunctival Flaps for Corneal Disease. In: Tasman W, Jaeger EA, eds, Duane’s Clinical Ophthalmology. Philadelphia:JB Lippincott, 2012, vol 6, chap 33. Del Monte MA. Neurocutaneous Syndromes. In: Wright KW, Strube YJ, eds, Pediatric Ophthalmology and Strabismus, 3rd edition. New York, NY: Oxford University Press, 2012, pp 1167-97. Del Monte MA. Ocular Anatomy and Physiology. In: Rudolph C, Lister G, Gershon A, First L, Rudolph A, eds, Rudolph’s Pediatrics, 22nd edition. New York, NY:McGraw-Hill, 2012, chap 579, pp 2273-5.
Douglas RS, Gupta S, Smith TJ. Pathogenesis and Medical Management of Thyroid Eye Disease. In: Black EH, Nesi FA, Gladstone GJ, Levine MR, Calvano CJ, eds, Smith and Nesi’s Ophthalmic Plastic & Reconstructive Surgery, 3rd Edition. New York:Springer, 2012, pp 1213-23. Enzenauer R, Hoehn ME, Del Monte MA. Strabismus. In: Rudolph C, Lister G, Gershon A, First L, Rudolph A, eds, Rudolph’s Pediatrics, 22nd edition. New York, NY:McGraw-Hill, 2012, chap 586, pp 2293-8. Gupta S, Demirci H, Lee BL, Elner VM, Kahana A. Orbital Inflammatory Diseases. In: Black EH, Nesi FA, Gladstone GJ, Levine MR, Calvano CJ, eds, Smith and Nesi’s Ophthalmic Plastic & Reconstructive Surgery, 3rd Edition. New York:Springer, 2012, pp 933-58. Hackel RE. Ophthlamic Photography. In: Stein HA, Stein RM, Freeman MI, eds, Ophthalmic Assistant: A Text for Allied and Associated Ophthalmic Personnel, 9th edition. New York: Elsevier, 2012. John DA, Weizer JS. Selective Laser Trabeculoplasty. In: Kahook M, ed, Essentials of Glaucoma Surgery. Thorofare, NJ:SLACK Inc. 2012, chap 21, pp 185196. Kahana A. Transcranial Approach to the Orbit. In: Black EH, Nesi FA, Gladstone GJ, Levine MR, Calvano CJ, eds, Smith and Nesi’s Ophthalmic Plastic & Reconstructive Surgery, 3rd Edition. New York:Springer, 2012, pp 807-10. Kahana, A. Orbital Vascular Anomalies. In: Black EH, Nesi FA, Gladstone GJ, Levine MR, Calvano CJ, eds, Smith and Nesi’s Ophthalmic Plastic & Reconstructive Surgery, 3rd Edition. New York:Springer, 2012, pp 993-1004.
Raoof D, Mian SI. Femtosecond laserassisted astigmatism correction. In: Goggin M, ed, Astigmatism - Optics, Physiology and Management, New York, New York:InTech Publishing, 2012, chap 13. Rumery TC, Musch DC, Stein JD. Review of Glaucoma Surgery Clinical Trials. In: Kahook MY, ed., Essentials of Glaucoma Surgery. Thorofare, NJ: SLACK Inc., 2012, chap 43, pp. 351-72. Saponara F, Stein JD. Comparison of Argon Laser Trabeculoplasty and Selective Laser Trabeculoplasty. In: Kahook M, ed, Essentials of Glaucoma Surgery. Thorofare, NJ:SLACK Inc. 2012, chap 22, pp 197-201. Stein JD. Preoperative Evaluation for Glaucoma Drainage Device Surgery. In: Kahook M, ed, Essentials of Glaucoma Surgery. Thorofare, NJ:SLACK Inc. 2012, chap 6, pp 61-71. Stein JD. Standard Technique for Implanting Glaucoma Drainage Devices. In: Kahook M, ed, Essentials of Glaucoma Surgery. Thorofare, NJ:SLACK Inc. 2012, chap 8 pp 81-94. Stratton R, Hauswirth W, Gardner TW. Studies on Retinal and Choroidal Disorders. New York:Humana, 2012. Szymarek TN, Moroi, SE, Eisengart JA. Glaucoma Surgery in the Nanophthalmic Eye. In: Kahook M, ed, Essentials of Glaucoma Surgery. Thorofare, NJ:SLACK Inc. 2012, chap 33, pp 285-291. Tombran-Tink J, Barnstable CJ, Gardner TW. Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement. New York:Springer, 2012. Trobe JD. The Physician’s Guide to Eye Care, 4th Edition. San Francisco:American Academy of Ophthalmology, 2012.
Innovation in vision
External grants and Funding July 1, 2011 — June 30, 2012
Fa cult y N a m e S ou rc e ID
P r oje ct Tit le
S. Abcouwer, Ph.D.
Regulation of Retinal Cell Death in Diabetes; Co-I
JDRF Center for Mechanisms and Intervention of Diabetic Retinopathy; Project 2 Co-PI
D. Antonetti, Ph.D.
Induction of the Blood-Retinal Barrier
Mechanisms of Retinal Vascular Permeability in Diabetes The Retinal Microenvironment in Diabetic Retinopathy
Subcontract with Northwestern University, PI: Robert Linsenmeier, Ph.D.
JDRF Developing Atypical PKC Inhibitors to Treat
JDRF Center for Mechanisms and Intervention of Diabetic Retinopathy; Project 2 Co-PI PolyChromatic Angiography for Grading Retinal
Vascular Leakage RPB
Jules and Doris Stein RPB Professorship
G. Comer, M.D., M.S. Lowy Medical Research Institute/ A Natural History Study of Macular Telangiectasia — Clinical Trial The MacTel Study Ocuscience Phase II/III Study of the Efficacy and Safety of Macuclear MC-1101 1% TID in the Treatment of Nonexudative AMD Ocuscience Reproducibility and Tolerability of Visual Tests Used to Evaluate Nonexudative AMD W. Cornblath, M.D. ICON Clinical Research/Pfizer Case-Crossover Study of PDE5 Inhibitor Exposure as a Potential “Trigger Factor” for Acute NAION H. Demirci, M.D. Midwest Eye-Banks Roles of Inflammation and Angiogenesis in Conjunctival Melanoma: Progression and Metastasis R. Douglas, M.D., Ph.D. NIH R01-EY211197-02 Role of CD40+ Fibrocytes in Thyroid-Associated Ophthalmopathy RPB Lew R. Wasserman Merit Award S. Elner, M.D. NIH/Clinical Trial U10-EY014660-06 Multicenter Uveitis Steroid Treatment (MUST) Trial Coordinating Center: Johns Hopkins University Santen Pharmaceutical Intravitreal Injections of DE-109 for the Treatment of Active, Non-Infectious Uveitis P. Fort, Ph.D. Fight for Sight Detailed Analysis of Crystallins Cellular and Sub-Cellular Upregulation During Diabetic Retinopathy Midwest Eye-Banks Characterization of Crystallin Proteins Expression in Human Retina: Effect of Diabetes
university of michigan kellogg eye center
External grants and Funding July 1, 2011 â€” June 30, 2012
Fa cult y N a m e S ou rc e ID
P r o je ct Tit le
P. Gage, Ph.D. NIH R01-EY014126-09 Pitx2: Molecular Mechanisms in Eye Development and Disease T. Gardner, M.D., M.S. NIH R01-EY020582-04 Regulation of Retinal Cell Death in Diabetes NIH DP3-DK094292-01 Metabolic Reprogramming in Diabetic Complications; Subaccount with Frank C. Brosius, M.D., Department of Nephrology, University of Michigan NIH/Clinical Trial U10EY14231 Prompt Panretinal Photocoagulation (Protocol S), Coordinating Center: Jaeb NIH/Clinical Trial U10EY01423 Genes in Diabetic Retinopathy, Coordinating Center: Jaeb American Diabetes Association Regulation of Akt Activity in Diabetic Retinopathy JDRF JDRF Center for Mechanisms and Intervention of Diabetic Retinopathy JDRF Evaluation of Retinal Sensory Neuropathy Study Midwest Eye-Banks A Diabetic Retinopathy Risk of Progression Calculator RPB Physician-Scientist Award R01-DC009606-03 Olfactory Signaling, Cilia, and Sensory Disorders J. Heckenlively, M.D. NIH Subaccount with Jeffrey Martens, Ph.D., Department of Pharmacology, University of Michigan NIH R01-EY016862-05 Genetic Variations in Age-Related Macular Degenerations NIH R21-EY-022172-01 Investigation of Autoimmune Anti-Retinal Antibodies in Diabetes FFB Center for the Study of Retinal Degenerative Diseases FFB Consortium Treatment Grant: Assessment of Therapies NNRI NNSP-CL-0212- A Phase II Multiple Site, Randomized, Placebo-Controlled 0061-MICH-NER Trial of Oral Valproic Acid Ocuscience Ocusciences Photography Project Sramek Foundation Interactive and Integrated Genetic Databases for the Study of Age-Related Macular Degeneration P. Hitchcock, Ph.D. NIH R01-EY007060-23 Neuronal Development, Injury and Repair in Retina NIH T32-EY013934-10 Vision Research Training Program Midwest Eye-Banks Regulation of Retina-Specific Gene Expression B. Hughes, Ph.D.
Core Center for Vision Research (five core modules) Ion Conductances in the Retinal Pigment Epithelium
M. Johnson, M.D. Midwest Eye-Banks Student Stipend Award for Natalia Bajenova, M.D. A. Kahana, M.D., Ph.D. NIH K08-EY018689-05 Zebrafish Model for Studying Orbital Development and Disease Alliance for Vision Research Biological Signals Controlling Extraocular Muscle Regeneration Alliance for Vision Research Chemical Genomic Screen for Modifiers of Axenfeld-Rieger Syndrome: A Pilot Study to Identify Novel Therapeutics of Anterior Segment Dysgenesis
Innovation in vision
External grants and Funding July 1, 2011 â€” June 30, 2012
Fa cult y N a m e S ou rc e ID
P r oje ct Tit le
A. Kahana, M.D., Ph.D. Alliance for Vision Research Investigating the Role of Extracellular Matrix Factors and (cont.) Collective Cell Migration in Extraocular Muscle Repair and Regeneration Using a Zebrafish Model Alliance for Vision Research Investigating the Roles of Twist1 and Twist2 in Extraocular Muscle Biology and Orbital Rhabdomyosarcoma Alliance for Vision Research Thyroid-Related Eye Disease: A Preclinical Study Investigating the Role of Retinoid Receptors in Mediating Orbitopathy Fight for Sight Developing Genomic Technologies to Study Extraocular Muscle Organization and Strabismus Using a Zebrafish Model; Award for Brenda Bohnsack, M.D., Ph.D. Fight for Sight Development and Regeneration of Extraocular Muscles in Zebrafish - Student Stipend Award for U-M Medical Student Daniel Kasprick RPB Career Development Award P. Lichter, M.D. RPB Unrestricted Grant VisionCare Ophthalmic Technologies/ VisionCare Ophthalmic Technologies Implantable Clinical Trial Miniature Telescope for Central Vision Impairment Associated with Age-Related Macular Degeneration and Other Maculopathies M. Lipson, O.D. EyeVis, L.L.C. Stabilizing Myopia by Accelerated Reshaping Technique SynergEyes, Inc. Duette Versus Biofinity Toric: Visual Acuity and Vision-Related Quality of Life S. Mian, M.D. Alliance for Vision Research Cost-Effectiveness of Endothelial Keratoplasty Compared with Penetrating Keratoplasty Bausch & Lomb, Inc. Treatment of Ocular Graft-versus-Host Disease (GVHD) with Topical Loteprednol Etabonate 0.5% Midwest Eye-Banks Outcomes of Refractive Surgery Performed by Trainees R01-EY-022124-01 Aqueous Humor Dynamic Components that Determine S. Moroi, M.D., Ph.D. NIH Intraocular Pressure Variance Merck and Company, Inc. Merck IISP #31911 Study: Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions D. Musch, Ph.D., M.P.H. NIH R21-EY-020912-02 Clinical and Quality of Life Insights on Glaucoma from Analyses of CIGTS Data NIH RC1-EY020140-01 Comparative Effectiveness and Medical Interventions for Primary Open-Angle Glaucoma; Subcontract with Johns Hopkins University M-CASTL A Survey of Vision Care Providers for Older Drivers Pfizer Value Estimation Project in Glaucoma (Phase III)
university of michigan kellogg eye center
External grants and Funding July 1, 2011 â€” June 30, 2012
Fa cult y N a m e S ou rc e ID
P r o je ct Tit le
C. Nelson, M.D. NIH R01 EY019497-03 Genetic Basis of Congenital Anophthalmia; Subaccount with Thomas Glaser, Ph.D., Departments of Internal Medicine and Human Genetics, University of Michigan Midwest Eye-Banks Economic Factors that Influence Blepharoplasty and Ectropion Repairs H. Petty, Ph.D. NIH R21 EY019986-01A1 Novel Immunofluorescence Methods for Retinal Research Elsa U. Pardee Foundation Pilot Studies on the Anti-Tumor Capacity of Novel Catalytic Nanoparticles D. Puro, M.D., Ph.D.
Retinovascular Physiology and Pathobiology
J. Richards, Ph.D. NIH R01-EY011671-11 Molecular Genetics of Primary Open-Angle Glaucoma NIH R21 EY021000-02 Ocular Effects of Metformin NSF CMMI 1130275 Mechanics of Intraocular Pressure Increase Associated with Genetic Factors Subaccount with Alan Argento, Ph.D., Department of Mechanical Engineering, University of Michigan Dearborn R. Shtein, M.D., M.S. NIH K23-EY017885-04 Neovascularization Patterns in Corneal Graft Rejection NIH P60-DK020572-34 In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy; Subaccount with Michigan Diabetes Research and Training Center, University of Michigan, Co-PI Midwest Eye-Banks Diagnostic Imaging for Intraoperative Floppy Iris Syndrome U-M Medical School Clinical Sciences Scholars Program Award T. Smith, M.D. NIH R01-DK063121-05 Immunoglobulin Activation of Fibroblasts NIH R01-EY008976-18 Regulation of Retroocular Connective Tissue NIH R01-EY011708-16 Functional Diversity of Orbital Fibroblasts Howard Hughes Fibrocytes as a Potential Biomarker for Thyroid-Associated Medical Institute Ophthalmopathy; Research Training Fellowship for U-M Medical Student Erin Gillespie RPB Physician-Scientist Award NIH K23-EY019511-03 Association between Cataract Surgery and Progression J. Stein, M.D., M.S. of Diabetic Retinopathy NIH P60-DK020572 Cost-Effectiveness of Different Treatments for Clinically Significant Diabetic Macular Edema; Subcontract with Michigan Diabetes Research and Training Center, University of Michigan Alliance for Vision Research A Diabetic Retinopathy Progression Risk Calculator American Glaucoma Society Mentoring for Advancement of Physician-Scientist Enabling Award Program
Innovation in vision
External grants and Funding July 1, 2011 â€” June 30, 2012
Fa cult y N a m e S ou rc e ID
P r oje ct Tit le
J. Stein, M.D., M.S. Blue Cross Blue Shield of Michigan Longitudinal Rates of Postoperative Adverse Outcomes (cont.) after Glaucoma Surgery among Medicare Beneficiaries 1994â€“2005 RPB Physician-Scientist Award A. Sugar, M.D.
NIH/Clinical Trial NIH/Clinical Trial
Cornea Donor Study, Coordinating Center: Jaeb Corneal Preservation Time Study, Coordinating Center: Jaeb
D. Thompson, Ph.D. NIH R21-EY020967-01 Chromophore Effects in Genetically Diverse Forms of Retinal Dystrophy FFB Consortium Treatment Grant: Small Molecular Interventions FFB Gene-Replacement Therapy for XLRP Due to RPGR Mutations - Continuation Midwest Eye-Banks Chromophore Therapy in Retinal Degeneration RDH12 Fund for Sight Gene-Replacement Therapy for RDH12 Mutations K. Wong, Ph.D. NIH R00-EY018863-05 Cross-Talk between Ganglion-Cell Photoreceptors and Other Neurons in the Retina Midwest Eye-Banks Functional Characterization of Developmental Changes in NMDA Receptor Subunit Composition of Retinal Ganglion Cells RPB Career Development Award R01-EY020823-03 Autophagy and Control of Photoreceptor Apoptosis D. Zacks, M.D., Ph.D. NIH Beckman Foundation Autophagy and Age-Related Macular Degeneration FFB Center for the Study of Retinal Degenerative Diseases FFB Consortium Treatment Grant: Transplantation of Photoreceptor Precursors Lincy Foundation Preventing Photoreceptor Cell Death in Age-Related Macular Degeneration
FFB..................... Foundation Fighting Blindness JDRF.................. Juvenile Diabetes Research Foundation International M-CASTL......... Michigan Center for Advancing Safe Transportation throughout the Lifespan NIH.................... National Institutes of Health NNRI................. National Neurovision Research Institute NSF.................... National Science Foundation RPB..................... Research to Prevent Blindness
university of michigan kellogg eye center
Philip J. Gage, Ph.D. Vision Research
Faculty of the Department of Ophthalmology and Visual Sciences
Leadership Paul P. Lee, M.D., J.D. Chair Alan Sugar, M.D. Vice Chair Michael W. Smith-Wheelock, M.D. Associate Chair for Clinical Affairs Shahzad I. Mian, M.D. Associate Chair for Education Thomas W. Gardner, M.D., M.S. Associate Chair for Research Section Chiefs Jill E. Bixler, M.D. Comprehensive Ophthalmology Donna M. Wicker, O.D., FAAO Contact Lens, Low Vision and Visual Rehabilitation
Terry J. Bergstrom, M.D. Comprehensive Ophthalmology Donald S. Beser, M.D., FACS Comprehensive Ophthalmology Cagri G. Besirli, M.D., Ph.D. Retina and Uveitis Brenda L. Bohnsack, M.D., Ph.D. Pediatric Ophthalmology and Adult Strabismus Kari Branham, M.S., C.G.C. Genetic Counseling Grant M. Comer, M.D., M.S. Retina and Uveitis Theresa M. Cooney, M.D. Cornea and External Disease, Cataract and Refractive Surgery Wayne T. Cornblath, M.D. Neuro-Ophthalmology
Christopher Gappy, M.D. Pediatric Ophthalmology and Adult Strabismus
Michael J. Lipson, O.D., FAAO Contact Lens, Low Vision and Visual Rehabilitation Xuwen Liu, M.D., Ph.D. Research Investigator
Hilary M. Grabe, M.D. Neuro-Ophthalmology
David C. Musch, Ph.D., M.P.H. Vision Research
Daniel G. Green, Ph.D. Vision Research
Arivalagan Muthusamy, Ph.D. Research Investigator
Paul J. Grenier, O.D. Comprehensive Ophthalmology
Gale A. Oren, M.I.L.S. Library
Richard E. Hackel, M.A., C.R.A. Ophthalmic Photography
Hemant Pawar, Ph.D. Vision Research
John R. Heckenlively, M.D. Retina and Uveitis
Howard R. Petty, Ph.D. Vision Research
Peter F. Hitchcock, Ph.D. Vision Research
Donald G. Puro, M.D., Ph.D. Comprehensive Ophthalmology
Christopher T. Hood, M.D. Cornea and External Disease, Cataract and Refractive Surgery
Julia E. Richards, Ph.D. Vision Research
Bret A. Hughes, Ph.D. Vision Research Ida L. Iacobucci, C.O. Pediatric Ophthalmology and Adult Strabismus Diane M. Jacobi, O.D. Contact Lens, Low Vision and Visual Rehabilitation
Frank W. Rozsa, Ph.D. Research Investigator Gary S. Sandall, M.D., FACS Pediatric Ophthalmology and Adult Strabismus Roni M. Shtein, M.D. Cornea and External Disease, Cataract and Refractive Surgery
Thiran Jayasundera, M.D., FRCSC, FRANZCO Retina and Uveitis
Terry J. Smith, M.D. Eye Plastic, Orbital and Facial Cosmetic Surgery Endocrinology
Denise A. John, M.D., FRCSC Glaucoma, Cataract and Anterior Segment Disease
Joshua D. Stein, M.D., M.S. Glaucoma, Cataract and Anterior Segment Disease
Hakan Demirci, M.D. Orbital and Ocular Oncology
Alon Kahana, M.D., Ph.D. Eye Plastic, Orbital and Facial Cosmetic Surgery
Bradley W. Taylor, O.D., M.P.H. Contact Lens, Low Vision and Visual Rehabilitation
Jonathan D. Trobe, M.D. Neuro-Ophthalmology
Courtney A. Dewey, O.D. Pediatric Ophthalmology and Adult Strabismus
Ariane D. Kaplan, M.D. Comprehensive Ophthalmology
Debra A. Thompson, Ph.D. Vision Research
Monte A. Del Monte, M.D. Pediatric Ophthalmology and Adult Strabismus
Raymond S. Douglas, M.D., Ph.D. Eye Plastic, Orbital and Facial Cosmetic Surgery
Harjeet Kaur, M.D., FRCS(I) Comprehensive Ophthalmology
Susan S. Thoms, M.D. Comprehensive Ophthalmology
Mark W. Johnson, M.D. Retina and Uveitis
Elizabeth Du, M.D. Comprehensive Ophthalmology
Naheed W. Khan, Ph.D. Vision Research
Joshua P. Vrabec, M.D. Comprehensive Ophthalmology
Adrienne L. West, M.D. At large
Susan G. Elner, M.D. Retina and Uveitis
Jennifer A. Kozak, M.D. Pediatric Ophthalmology and Adult Strabismus
Jennifer S. Weizer, M.D. Glaucoma, Cataract and Anterior Segment Disease
Victor M. Elner, M.D., Ph.D. Eye Plastic, Orbital and Facial Cosmetic Surgery
Amy L. Lagina, O.D. Contact Lens, Low Vision and Visual Rehabilitation
Kwoon Y. Wong, Ph.D. Vision Research
H. Kaz Soong, M.D. Cornea and External Disease, Cataract and Refractive Surgery
Sherry H. Day, O.D. Contact Lens, Low Vision and Visual Rehabilitation
Christine C. Nelson, M.D., FACS Eye Plastic, Orbital and Facial Cosmetic Surgery
Karen S. DeLoss, O.D. Contact Lens, Low Vision and Visual Rehabilitation
Sayoko E. Moroi, M.D., Ph.D. Glaucoma, Cataract and Anterior Segment Disease
Steven F. Abcouwer, Ph.D. Vision Research James L. Adams, M.D. Eye Plastic, Orbital and Facial Cosmetic Surgery David A. Antonetti, Ph.D. Vision Research Steven M. Archer, M.D. Pediatric Ophthalmology and Adult Strabismus
Jerome I. Finkelstein, M.D., FACS Comprehensive Ophthalmology Patrice E. Fort, Ph.D. Vision Research Carlton J. Foster, O.D. Pediatric Ophthalmology and Adult Strabismus Bruce A. Furr, C.O., M.S.P.H. Pediatric Ophthalmology and Adult Strabismus
Helios T. Leung, Ph.D., O.D., FAAO Contact Lens, Low Vision and Visual Rehabilitation Paul R. Lichter, M.D., FACS Glaucoma, Cataract and Anterior Segment Disease Cheng-mao Lin, Ph.D. Vision Research
Maria A. Woodward, M.D. Cornea and External Disease, Cataract and Refractive Surgery Rebecca A. Wu, M.D. Comprehensive Ophthalmology Dongli Yang, M.D., Ph.D. Research Investigator David N. Zacks, M.D., Ph.D. Retina and Uveitis
W.K. Kellogg Eye Center
Faculty of the Department of Ophthalmology and Visual Sciences 1st Row: Thomas W. Gardner, M.D., M.S., Shahzad I. Mian, M.D., Paul P. Lee, M.D., J.D., Alan Sugar, M.D. 2nd Row: Jonathan D. Trobe, M.D., Jill E. Bixler, M.D., H. Kaz Soong, M.D., Mark W. Johnson, M.D., Monte A. Del Monte, M.D., Christine C. Nelson, M.D., Sayoko E. Moroi, M.D., Ph.D., Denise A. John, M.D. 3rd Row: John R. Heckenlively, M.D., James L. Adams, M.D., Kwoon Y. Wong, Ph.D., Steven M. Archer, M.D., Gary S. Sandall, M.D., Susan S. Thoms, M.D., Alon Kahana, M.D., Ph.D., Joshua P. Vrabec, M.D., Elizabeth Du, M.D. 4th Row: Hilary M. Grabe, M.D., Theresa M. Cooney, M.D., Wayne T. Cornblath, M.D., Peter F. Hitchcock, Ph.D., Debra A. Thompson, Ph.D., Donald G. Puro, M.D., Ph.D., Bruce A. Furr, C.O., David C. Musch, Ph.D., M.P.H., Roni M. Shtein, M.D., M.S., Grant M. Comer, M.D., M.S., Jennifer A. Kozak, M.D., Rebecca A. Wu, M.D. 5th Row: Joshua D. Stein, M.D., M.S., Patrice E. Fort, Ph.D., M.S., Jerome I. Finkelstein, M.D., Terry J. Bergstrom, M.D., Amy L. Lagina, O.D., Bradley W. Taylor, O.D., M.P.H., Karen S. DeLoss, O.D., Christopher T. Hood, M.D. 6th Row: Richard E. Hackel, M.A., C.R.A., Steven F. Abcouwer, Ph.D., Michael J. Lipson, O.D., Philip J. Gage, Ph.D., Bret A. Hughes, Ph.D., Christopher Gappy, M.D., Sherry H. Day, O.D., Courtney A. Dewey, O.D., Donna M. Wicker, O.D., Gale A. Oren, M.I.L.S., Brenda L. Bohnsack, M.D., Ph.D. 7th Row: Thiran Jayasundera, M.D., David A. Antonetti, Ph.D., Paul J. Grenier, O.D., Susan G. Elner, M.D., Hakan Demirci, M.D., David N. Zacks, M.D., Ph.D., Raymond S. Douglas, M.D., Ph.D., Maria A. Woodward, M.D., Helios T. Leung, Ph.D., O.D., Cheng-mao Lin, Ph.D.
Educating the next generation of ophthalmologists and vision scientists Our residents, clinical fellows, and research fellows are an important part of the Kellogg community, where they have the opportunity to forge close working relationships with faculty. At Kellogg we are committed to bringing new technologies and approaches to education to help our graduates meet the challenges of changing health care and research environments.
1st Year Residents Courtney Kauh, M.S., M.D. M.D. University of Toledo M.S. Ohio State University Mehnaz Khan, M.S., M.D. M.D. Vanderbilt University M.S. Johns Hopkins University Lee M. Kiang, M.D., Ph.D. M.D., Ph.D. Weill Cornell, Rockefeller, Sloan Kettering Ph.D. The Rockefeller University
Patricia A. Ple-plakon, M.D. M.D. University of Michigan Ira H. Schachar, M.D. M.D. Washington University in St. Louis M.Sc. Oxford University 3rd Year Residents Alexandra O. Apkarian, M.D. M.D. University of Michigan
Monica M. Michelotti, M.D. M.D. University of Michigan Melisa Nika, M.D. M.D. University of Michigan
Michael L. Bullard, M.D. M.D. University of Iowa
Andrew W. Stacey, M.D., M.S. M.D. Ohio State University M.S. Brigham Young University
Nicholas D. Chinskey, M.D. M.D. University of Michigan Abigail T. Fahim, M.D., Ph.D. M.D. Baylor University Ph.D. University of Michigan Ryan J. Fante, M.D. M.D. University of Colorado Denver Denise S. Kim, M.D. M.D. University of Michigan Crandall E. Peeler, M.D. M.D. Dartmouth College
Cesar A. Briceno, M.D. Eye Plastic, Orbital and Facial Cosmetic Surgery M.D. - Johns Hopkins University Residency - Doheny Eye Institute, University of Southern California Lindsey B. DeLott, M.D. Neuro-Ophthalmology M.D. - Ohio State University Residency - University of Michigan Nadeem H. Fatteh, M.D. Cornea and External Disease, Cataract and Refractive Surgery M.D. - Medical College of Georgia Residency - Georgia Health Sciences University Jonathan B. Greene, M.D. Cornea and External Disease, Cataract and Refractive Surgery M.D. - University of Michigan Residency - University of California
S. Asha Balakrishnan, M.D. M.D. Washington University in St. Louis
2nd Year Residents
Shivani Gupta, M.D., M.P.H. Eye Plastic, Orbital and Facial Cosmetic Surgery M.P.H. - University of Michigan M.D. - Ohio State University Residency - University of Illinois at Chicago Nieraj Jain, M.D. Vitreo-Retinal Surgical M.D. - Duke University Residency - Duke University
Jasleen K. Singh, M.D. Pediatric Ophthalmology and Adult Strabismus M.D. - Medical College of Georgia Residency - Northwestern University Jeffrey M. Sundstrom, M.D., Ph.D. Medical Retina Fellow M.D. - Pennsylvania State University Residency - Pennsylvania State University Linda Zhang, M.D. Glaucoma, Cataract and Anterior Segment Disease M.D. - University of Michigan Residency - University of Michigan Research Fellows Alma Rosa Barajas-Espinosa, Ph.D. Ph.D. Universidad Autonoma de San Luis Potosi, Mexico Edith Arnold Hernandez, Ph.D. Ph.D. National Autonomous University of Mexico Caiping Hu, M.D., Ph.D. Ph.D. Wayne State University Ph.D. Sun Yat-sen University, Guangzhou, Guangdong, Peoples Republic of China Bin Li, M.D., Ph.D. Ph.D. Ohio State University Jibiao Li, Ph.D. Ph.D. Kent State University Nupur Raychaudhuri, Ph.D. Ph.D. Bose Institute, Calcutta, India
Blake V. Fausett, M.D., Ph.D. M.D. University of Michigan Ph.D. University of Michigan
Partho S. Kalyani, M.D. Vitreo-Retinal Surgical M.D. - Northeastern Ohio Universities College of Medicine Residency - University of Arizona Fellowship - Jules Stein Eye Institute, University of California Los Angeles
Molly L. Fuller, M.D., Ph.D. M.D. Case Western Reserve University Ph.D. Case Western Reserve University
Allison N. McCoy, M.D., Ph.D. Eye Plastic, Orbital and Facial Cosmetic Surgery M.D. - Duke University Residency - Wilmer Eye Institute
Scott M. Taylor, Ph.D. Ph.D. Florida Institute of Technology
Kristen Harris Nwanyanwu, M.D., M.B.A. M.D. University of Pennsylvania M.B.A. University of Pennsylvania
Paula Anne Newman-Casey, M.D. Research / Comprehensive Ophthalmology M.D. - University of Michigan Residency - University of Michigan
Duna Raoof-Daneshvar, M.D. M.D. University of Michigan Travis Rumery, D.O. M.D. Des Moines University, College of Osteopathic Medicine
Shreya S. Prabhu, M.D., M.P.H. Pediatric Ophthalmology and Adult Strabismus M.D. - Boston University Residency - University of Michigan
Shameka J. Shelby, Ph.D. Ph.D. University of Michigan Benjamin K. Stafford, Ph.D. Ph.D. University of California, Santa Cruz
Wei Zhang, Ph.D. Ph.D. Institute of Developmental Biology, Shandong University, Peoples Republic of China Xiwu Zhao, Ph.D. Ph.D. Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
The W.K. Kellogg Eye Center at the University of Michigan has
Executive Officers of the University of Michigan Health System Ora Hirsch Pescovitz, M.D. Executive Vice President for Medical Affairs
again been named one of the
Douglas L. Strong, M.B.A. Chief Executive Officer, U-M Hospitals and Health Centers
top ophthalmology programs in
James O. Woolliscroft, M.D. Dean, U-M Medical School
the country by U.S. News & World Report. In this survey, ophthalmologists select the programs where patients receive the best care for the most complex or
The Regents of the University of Michigan Julia Donovan Darlow, Laurence B. Deitch, Denise Ilitch, Olivia P. Maynard, Andrea Fischer Newman, Andrew C. Richner, S. Martin Taylor, Katherine E. White, Mary Sue Coleman (ex officio) Editor: Betsy Nisbet Writers: Aimee Bergquist, Barbara Sefton Editorial Assistant: Lisa Burkhart Design and Art Direction: David Murrel
Photographers: Eric Bronson, Scott Soderberg, Austin Thomason, U-M Photo Services; Lin Goings, U-M Department of Ophthalmology and Visual Sciences; Leisa Thompson, Leisa Thompson Photography
For additional copies, please contact us: University of Michigan Department of Ophthalmology and Visual Sciences W.K. Kellogg Eye Center 1000 Wall Street Ann Arbor, Michigan 48105 734.763.4660 â€˘ www.kellogg.umich.edu For patient queries, please call 734.763.8122